| |
Mandatory publication pursuant to
Sec. 34, 14 paras. 2 and 3 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, WpÜG) |
| |
| |
Shareholders of QIAGEN N.V., in particular those who have their place of residence, seat or place of habitual abode in the United States of America or otherwise outside the Federal Republic of Germany, The Netherlands and the other member states of the European Union and the European Economic Area should pay particular attention to the information contained in Section 1 of this Offer Document.
|
| |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 28 | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 34 | | | |
| | | | | 34 | | | |
| | | | | 34 | | | |
| | | | | 35 | | | |
| | | | | 38 | | | |
| | | | | 38 | | | |
| | | | | 39 | | | |
| | | | | 39 | | | |
| | | | | 39 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 41 | | | |
| | | | | 42 | | | |
| | | | | 42 | | | |
| | | | | 43 | | | |
| | | | | 43 | | | |
| | | | | 43 | | | |
| | | | | 43 | | | |
| | | | | 45 | | | |
| | | | | 48 | | | |
| | | | | 49 | | | |
| | | | | 50 | | | |
| | | | | 52 | | | |
| | | | | 52 | | | |
| | | | | 52 | | | |
| | | | | 52 | | | |
| | | | | 52 | | | |
| | | | | 52 | | | |
| | | | | 52 | | | |
| | | | | 54 | | | |
| | | | | 54 | | | |
| | | | | 54 | | | |
| | | | | 55 | | | |
| | | | | 55 | | | |
| | | | | 55 | | | |
| | | | | 57 | | | |
| | | | | 57 | | | |
| | | | | 57 | | | |
| | | | | 58 | | |
| | | | | 58 | | | |
| | | | | 59 | | | |
| | | | | 59 | | | |
| | | | | 60 | | | |
| | | | | 61 | | | |
| | | | | 61 | | | |
| | | | | 62 | | | |
| | | | | 62 | | | |
| | | | | 63 | | | |
| | | | | 63 | | | |
| | | | | 63 | | | |
| | | | | 63 | | | |
| | | | | 64 | | | |
| | | | | 64 | | | |
| | | | | 64 | | | |
| | | | | 64 | | | |
| | | | | 65 | | | |
| | | | | 65 | | | |
| | | | | 65 | | | |
| | | | | 66 | | | |
| | | | | 66 | | | |
| | | | | 66 | | | |
| | | | | 66 | | | |
| | | | | 66 | | | |
| | | | | 66 | | | |
| | | | | 67 | | | |
| | | | | 68 | | | |
| | | | | 68 | | | |
| | | | | 69 | | | |
| | | | | 69 | | | |
| | | | | 69 | | | |
| | | | | 69 | | | |
| | | | | 70 | | | |
| | | | | 70 | | | |
| | | | | 70 | | | |
| | | | | 71 | | | |
| | | | | 71 | | | |
| | | | | 71 | | | |
| | | | | 71 | | | |
| | | | | 73 | | | |
| | | | | 73 | | | |
| | | | | 74 | | | |
| | | | | 74 | | |
| | | | | 74 | | | |
| | | | | 75 | | | |
| | | | | 75 | | | |
| | | | | 75 | | | |
| | | | | 76 | | | |
| | | | | 77 | | | |
| | | | | 77 | | | |
| | | | | 77 | | | |
| | | | | 77 | | | |
| | | | | 78 | | | |
| | | | | 78 | | | |
| | | | | 78 | | | |
| | | | | 79 | | | |
| | | | | 79 | | | |
| | | | | 80 | | | |
| | | | | 81 | | | |
| | | | | 81 | | | |
| | | | | 82 | | | |
| | | | | 82 | | | |
| | | | | 82 | | | |
| | | | | 83 | | | |
| | | | | 83 | | | |
| | | | | 83 | | | |
| | | | | 84 | | | |
| | | | | 84 | | | |
| | | | | 84 | | | |
| | | | | 87 | | | |
| | | | | 87 | | | |
| | | | | 87 | | | |
| | | | | 87 | | | |
| | | | | 88 | | | |
| | | | | 89 | | | |
| | | | | 90 | | | |
| | | | | 90 | | | |
| | | | | 91 | | | |
| | | | | 91 | | | |
| | | | | 92 | | | |
| | | | | 93 | | | |
| | | | | 94 | | |
| | | | | 95 | | | |
| | | | | 96 | | | |
| | | | | 96 | | | |
| | | | | 96 | | | |
| | | | | 97 | | | |
| | | | | 98 | | | |
| | | | | 98 | | | |
| | | | | 98 | | | |
| | | | | 102 | | | |
| | | | | 108 | | | |
| | | | | 108 | | | |
| | | | | 111 | | | |
| | | | | 111 | | | |
| | | | | 112 | | | |
| | | | | 113 | | | |
| | | | | 113 | | | |
| | | | | 114 | | | |
| | | | | 114 | | | |
| | | | | 115 | | | |
| | | | | 116 | | | |
| | | | | 119 | | | |
| | | | | 120 | | | |
| | | | | 121 | | | |
| | | | | 122 | | | |
| | | | | 122 | | | |
| | | | | 122 | | | |
| | | | | 123 | | | |
| | | | | 148 | | | |
| | | | | 150 | | |
Term
|
| |
Section
|
|
2014 QIAGEN Call Options
|
| |
7.2.2
|
|
2014 QIAGEN Warrants
|
| |
7.2.2
|
|
2017 QIAGEN Call Options
|
| |
7.2.2
|
|
2017 QIAGEN Warrants
|
| |
7.2.2
|
|
2018 QIAGEN Call Options
|
| |
7.2.2
|
|
2018 QIAGEN Warrants
|
| |
7.2.2
|
|
2025 Notes
|
| |
14.2(b)
|
|
2027 Notes
|
| |
14.2(b)
|
|
2030 Notes
|
| |
14.2(b)
|
|
2032 Notes
|
| |
14.2(b)
|
|
ACCC
|
| |
11.1.4
|
|
Acceptance Period
|
| |
5.2
|
|
Action
|
| |
8.2.13
|
|
Additional Acceptance Period
|
| |
5.3
|
|
Adjusted RSU
|
| |
18.1
|
|
Administrative Agent
|
| |
14.2(a)
|
|
Adverse Recommendation Change
|
| |
8.2.3
|
|
Affiliate
|
| |
2.2
|
|
AFM
|
| |
1.1
|
|
Agent’s Message
|
| |
13.2.2
|
|
Alternative Proposal
|
| |
8.2.14
|
|
Antitrust Clearance
|
| |
8.2.13
|
|
Antitrust Clearance Condition
|
| |
12.2
|
|
Antitrust Division
|
| |
11.1.2
|
|
Antitrust Investigation
|
| |
8.2.13
|
|
April Notes
|
| |
14.2(b)
|
|
Asset Sale
|
| |
8.5.7
|
|
Asset Sale Agreement
|
| |
8.5.7
|
|
Asset Sale and Liquidation
|
| |
8.5.8
|
|
AWV
|
| |
11.3
|
|
Back-End Resolution
|
| |
8.3(i)
|
|
BaFin
|
| |
1.1
|
|
Banking Day
|
| |
2.1
|
|
BCA Business Day
|
| |
2.1
|
|
Bernard Bonus Agreement
|
| |
18.2
|
|
Bernard Employment Agreement
|
| |
18.2
|
|
Bidder
|
| |
1.1
|
|
Bidder Parent
|
| |
1.1
|
|
Bidder Top Up Affiliate
|
| |
8.3(i)(A)
|
|
BMWi
|
| |
11.3
|
|
Book-Entry Confirmation
|
| |
13.2.2
|
|
Bridge Commitments
|
| |
14.2(a)
|
|
Bridge Credit Agreement
|
| |
14.2(a)
|
|
Business Combination Agreement
|
| |
1.4
|
|
Term
|
| |
Section
|
|
Cash Distribution
|
| |
8.5.5
|
|
Cash Distribution Amount
|
| |
8.5.5
|
|
Cash Payment
|
| |
8.5.5
|
|
CCCS
|
| |
11.1.4
|
|
CCSA
|
| |
11.1.4
|
|
Clearstream
|
| |
12.11
|
|
Clearstream Settlement Agent
|
| |
13.1.1
|
|
Clearstream Shares
|
| |
13
|
|
Closing Date
|
| |
14.2(a)
|
|
Code
|
| |
8.5.9
|
|
Commitment Letter
|
| |
14.2(b)
|
|
Company Recommendation
|
| |
8.2.3
|
|
Competing Offer
|
| |
8.2.14
|
|
Completion Date
|
| |
8.2.5
|
|
Compulsory Acquisition
|
| |
8.5.10
|
|
Consolidated EBIT
|
| |
12.8
|
|
Consolidated EBITDA
|
| |
12.8
|
|
Continuing Employee
|
| |
9.3.1
|
|
Custodian Bank
|
| |
13.1.2
|
|
D&O Insurance
|
| |
8.2.9
|
|
DCC
|
| |
7.8(d)
|
|
De Brauw
|
| |
8.1.2
|
|
Declaration of Acceptance
|
| |
13.1.2
|
|
Directly Registered Shares
|
| |
13
|
|
Domestic Paying Agent
|
| |
19.3.2(i)
|
|
DTC
|
| |
1.2
|
|
DTC Shares
|
| |
13
|
|
Dutch Courts
|
| |
8.2.20
|
|
Dutch GAAP
|
| |
15.2
|
|
Dutch Offer Rules
|
| |
1.1
|
|
Dutch Resident Entity
|
| |
19.2.2(ii)(a)
|
|
Dutch Resident Individual
|
| |
19.2.2(ii)(b)
|
|
EC
|
| |
11.1.1
|
|
EC Merger Regulation
|
| |
11.1.1
|
|
Eligible Institution
|
| |
13.2.2
|
|
EUR
|
| |
2.1
|
|
Exchange Act
|
| |
1.1
|
|
Executive Officer
|
| |
18.1
|
|
Explanatory Financial Information
|
| |
15
|
|
FAS
|
| |
11.1.4
|
|
Federal Reserve Board
|
| |
16(j)
|
|
FFIR
|
| |
11.3
|
|
Financial Threshold
|
| |
12.8
|
|
Financing Term Sheet
|
| |
14.2(b)
|
|
Foster Employment Agreement
|
| |
18.2
|
|
Foundation
|
| |
7.8
|
|
Term
|
| |
Section
|
|
Foundation Call Option
|
| |
7.8(a)
|
|
Foundation Call Option Agreement
|
| |
7.8(a)
|
|
Foundation Support Agreement
|
| |
7.8
|
|
Fractional QIAGEN Share
|
| |
4
|
|
FSE
|
| |
1.2
|
|
FTC
|
| |
11.1.2
|
|
GAAP
|
| |
2.1
|
|
German Business Day
|
| |
2.1
|
|
German Information Agent
|
| |
21
|
|
German Resident Corporation
|
| |
19.3.2(ii)(a)
|
|
German Resident Holders
|
| |
19.3.2(ii)(a)
|
|
German Resident Individual
|
| |
19.3.2(i)
|
|
German Solicitation Agent
|
| |
22
|
|
German Takeover Act
|
| |
1.1
|
|
Germany
|
| |
1.1
|
|
GM
|
| |
8.3
|
|
Governance Resolutions
|
| |
8.3
|
|
Governmental Authority
|
| |
8.2.15
|
|
HSR Act
|
| |
11.1.2
|
|
ICA
|
| |
11.1.4
|
|
Indemnified Person
|
| |
18.2
|
|
Independent Expert
|
| |
12.10
|
|
Independent Members
|
| |
8.2.5(ii)
|
|
Interim Period
|
| |
8.2.13
|
|
Intervening Event
|
| |
8.2.14
|
|
IRS
|
| |
19.1
|
|
JFTC
|
| |
11.1.4
|
|
JPMorgan
|
| |
14.2(a)
|
|
KFTC
|
| |
11.1.4
|
|
KStG
|
| |
19.3.3(ii)(a)
|
|
Law
|
| |
12.6
|
|
Letter of Transmittal
|
| |
13.2.2
|
|
Liquidation
|
| |
8.5.8
|
|
Liquidation Distribution
|
| |
3
|
|
Liquidator
|
| |
8.3
|
|
Loans | | |
14.2(a)
|
|
Long Stop Date
|
| |
3
|
|
Managing Board
|
| |
4
|
|
March Notes
|
| |
14.2(b)(ii)
|
|
Material Adverse Effect
|
| |
12.8
|
|
Material Compliance Violation
|
| |
12.9
|
|
Maximum Number of Top Up Shares
|
| |
8.3(i)(A)
|
|
Merger
|
| |
8.5.4
|
|
Merger and Liquidation
|
| |
8.5.8
|
|
Merger Resolution
|
| |
8.4
|
|
Minority Shareholder NFC
|
| |
8.2.5
|
|
Term
|
| |
Section
|
|
Minority Shareholders
|
| |
8.5.11
|
|
MIT
|
| |
6.3.4
|
|
MSSF
|
| |
14.2(b)(i)
|
|
Non-Financial Covenants
|
| |
8.2.5
|
|
Non-Tender Agreement
|
| |
14.1
|
|
Noon Buying Rate
|
| |
2.4.2
|
|
Notes | | |
14.2(b)
|
|
Notice of Guaranteed Delivery
|
| |
13.2.2
|
|
November 5th Proposal
|
| |
8.1.2
|
|
November 21st Proposal
|
| |
8.1.2
|
|
November 22nd Proposal
|
| |
8.1.2
|
|
NYSE
|
| |
1.1
|
|
NZCC
|
| |
11.1.4
|
|
October 18th Proposal
|
| |
8.1.2
|
|
Offer
|
| |
1.1
|
|
Offer Conditions
|
| |
12
|
|
Offer Costs
|
| |
14.1
|
|
Offer Document
|
| |
1.1
|
|
Offer Materials
|
| |
3
|
|
Offer Price
|
| |
4
|
|
Order
|
| |
12.6
|
|
Other Post-Offer Measures
|
| |
8.5.11
|
|
Parent Financing Commitment
|
| |
14.2
|
|
PFIC
|
| |
19.1
|
|
Piening Employment Agreement
|
| |
18.2
|
|
Post-Offer Measures
|
| |
8.5.2
|
|
Preference Shares Cancellation
|
| |
8.5.5
|
|
Premium Cap
|
| |
8.2.9
|
|
QIAGEN
|
| |
1.1
|
|
QIAGEN Boards
|
| |
4
|
|
QIAGEN Call Options
|
| |
7.2.2
|
|
QIAGEN Equity Plans
|
| |
7.2.3
|
|
QIAGEN Group
|
| |
3
|
|
QIAGEN Newco
|
| |
8.5.4
|
|
QIAGEN Newco Class A Share
|
| |
8.5.4
|
|
QIAGEN Newco Class B Share
|
| |
8.5.4
|
|
QIAGEN Newco Preference Share
|
| |
8.5.4
|
|
QIAGEN Newco Shares
|
| |
8.5.4
|
|
QIAGEN Newco Sub
|
| |
8.5.4
|
|
QIAGEN Newco Sub Election
|
| |
8.5.5
|
|
QIAGEN Option
|
| |
8.2.10(i)
|
|
QIAGEN Ordinary Shares
|
| |
8.3(i)(A)
|
|
QIAGEN PSU
|
| |
8.2.10(ii)
|
|
QIAGEN RSU
|
| |
7.2.3
|
|
QIAGEN Share
|
| |
1.1
|
|
QIAGEN Shareholder
|
| |
1.1
|
|
Term
|
| |
Section
|
|
QIAGEN Shareholders
|
| |
1.1
|
|
QIAGEN Shares
|
| |
1.1
|
|
QIAGEN Warrants
|
| |
7.2.2
|
|
Qualified Holding
|
| |
19.3.2(i)
|
|
Quebec
|
| |
1.1
|
|
Reasoned Position Statement
|
| |
7.7
|
|
Resolutions
|
| |
8.3
|
|
Reverse Termination Payment
|
| |
8.2.17
|
|
RFIs
|
| |
11.1.4
|
|
Sackers DE Employment Agreement
|
| |
18.2
|
|
Sackers Employment Agreements
|
| |
18.2
|
|
Sackers NL Employment Agreement
|
| |
18.2
|
|
Sackers U.S. Employment Agreement
|
| |
18.2
|
|
SAMR
|
| |
11.1.3
|
|
Schedule TO
|
| |
1.1
|
|
Schweins Employment Agreement
|
| |
18.2
|
|
SEC
|
| |
1.1
|
|
Securities Act
|
| |
8.2.20
|
|
Sell-Out Right
|
| |
16(e)
|
|
Settlement
|
| |
3
|
|
Settlement Agent
|
| |
13.2.1
|
|
Settlement Date
|
| |
3
|
|
SFIR
|
| |
11.3
|
|
Share Transfer
|
| |
8.5.6
|
|
Share Transfer Agreement
|
| |
8.5.6
|
|
Sheldon Employment Agreement
|
| |
18.2
|
|
Stock Exchange Trading Day
|
| |
2.1
|
|
Subsequent EGM
|
| |
8.4
|
|
Supervisory Board
|
| |
4
|
|
Tendered Clearstream Shares
|
| |
13.1.3(a)(i)
|
|
Term A-1 Facility
|
| |
14.2(b)
|
|
Term Loan Facility
|
| |
14.2(b)
|
|
Termination Payment
|
| |
8.2.17
|
|
TFTC
|
| |
11.1.4
|
|
Thermo Fisher
|
| |
1.1
|
|
Thermo Fisher Board
|
| |
8.1.2
|
|
Thermo Fisher Group
|
| |
1.1
|
|
Thermo Options
|
| |
18.2
|
|
Thermo RSUs
|
| |
18.2
|
|
Threshold Value Contract
|
| |
8.2.17
|
|
Threshold Value Transaction
|
| |
8.2.17
|
|
Top Up Option
|
| |
8.3(i)(A)
|
|
Transaction Committee
|
| |
8.1.2
|
|
Transaction Costs
|
| |
15.1.2(b)
|
|
Transaction Payment
|
| |
18.2
|
|
Transactions
|
| |
4
|
|
Term
|
| |
Section
|
|
Treasury Fractional Shares
|
| |
7.2.1
|
|
Treasury Ordinary Shares
|
| |
7.2.1
|
|
Treasury Shares
|
| |
7.2.1
|
|
U.S.
|
| |
1.1
|
|
U.S. Business Day
|
| |
2.1
|
|
U.S. Holder
|
| |
19.1
|
|
U.S. Information Agent
|
| |
1.4
|
|
U.S. Offer Rules
|
| |
1.1
|
|
United States
|
| |
1.1
|
|
USA
|
| |
1.1
|
|
USD
|
| |
2.1
|
|
Viola DE Employment Agreement
|
| |
18.2
|
|
Viola NL Employment Agreement
|
| |
18.2
|
|
Wachtell Lipton
|
| |
8.1.2
|
|
Waiver Letters
|
| |
18.1
|
|
WpÜG
|
| |
1.1
|
|
WpÜGAngebV
|
| |
1.1
|
|
WpÜGAnwendV
|
| |
1.1
|
|
Year Ended December 31,
|
| |
Average Rate
|
| |||
2019
|
| | | | 1.1184 | | |
2018
|
| | | | 1.1785 | | |
Month Ended
|
| |
Average Rate
|
| |||
April 2020
|
| | | | 1.0871 | | |
March 2020
|
| | | | 1.1046 | | |
February 2020
|
| | | | 1.0911 | | |
January 2020
|
| | | | 1.1098 | | |
December 2019
|
| | | | 1.1114 | | |
November 2019
|
| | | | 1.1051 | | |
|
Bidder:
|
| |
Quebec B.V.
Takkebijsters 1 4817 BL Breda The Netherlands |
|
|
Target Company:
|
| |
QIAGEN N.V.
Hulsterweg 82 5912 PL Venlo The Netherlands |
|
|
Subject of the Offer:
|
| | Acquisition of all QIAGEN Shares (ISIN NL0012169213; CUSIP N72482123) including all ancillary rights, in particular the entitlement to profits, existing at the time of the Settlement. | |
|
Consideration:
|
| |
EUR 39.00 per QIAGEN Share
Tendering holders of QIAGEN Shares that are held in the Depository Trust Company system or of Directly Registered Shares will receive U.S. dollars in exchange for such QIAGEN Shares upon the Settlement. The Offer Price will be converted using the simple average of the two WM/Reuters 4:00 p.m. (London time) fixings of the USD/EUR exchange rate on the second (2nd) and third (3rd) day prior to the date of the Settlement. Holders of QIAGEN Shares that are held in the Depository Trust Company system as well as holders of Directly Registered Shares should be aware that fluctuations in the Euro to U.S. dollar exchange rate will cause the value of U.S. dollar denominated consideration paid to them in respect of such shares to fluctuate accordingly. Additional details about the Offer, including details related to consideration, are included in Section 4.
As described in detail in Section 19, the tax consequences of receiving the Offer Price as a result of accepting the Offer may be more favorable to a tendering shareholder than the tax consequences of receiving cash in respect of QIAGEN Shares in a Liquidation Distribution. In particular, the applicable withholding taxes, including generally a 15% Dutch dividend withholding tax, and other taxes imposed on non-tendering QIAGEN Shareholders in respect of the Liquidation Distribution may be different from, and greater than, the taxes imposed upon such QIAGEN Shareholders had they tendered their QIAGEN Shares pursuant to the Offer. See Section 19 for additional information
|
|
| | | |
regarding material U.S., Dutch and German tax consequences for tendering and non-tendering QIAGEN Shareholders.
In addition, as described in Section 16, tendering QIAGEN Shareholders will be paid earlier than non-tendering QIAGEN Shareholders that receive payment in connection with any subsequent Post-Offer Measure (as defined in Section 8.5.2).
|
|
|
Acceptance Period:
|
| | May 18, 2020 to July 27, 2020, 24:00 hours (Frankfurt am Main local time)/18:00 hours (New York local time). | |
|
Additional Acceptance Period:
|
| | The Additional Acceptance Period (as defined in Section 5.3) is expected to commence on July 31, 2020 and end on August 13, 2020, 24:00 hours (Frankfurt am Main local time)/18:00 hours (New York local time). See Section 5.3 for additional information regarding the Additional Acceptance Period. | |
|
Offer Conditions:
|
| |
The Settlement and the agreements which have been entered into as a result of the acceptance of the Offer are subject to the conditions set forth in Section 12, which can be summarized as follows:
–
As further specified in Section 12.1, a minimum acceptance threshold of at least 75% of QIAGEN’s issued and outstanding ordinary share capital (geplaatst en uitstaand gewoon kapitaal), for the avoidance of doubt, excluding any QIAGEN Shares held by QIAGEN in treasury at the end of the Acceptance Period, having been achieved at the end of the Acceptance Period.
–
As further specified in Section 12.2, merger control approvals in the United States, the European Union, China and the other jurisdictions set forth in Section 11.1.4 having been obtained between the publication of the Offer Document and the Long Stop Date (defined below).
–
As further specified in Section 12.3, neither the Managing Board nor the Supervisory Board of QIAGEN having made an Adverse Recommendation Change (as defined in Section 8.2.3) in relation to an Intervening Event or a Competing Offer (in each case, as defined in Section 8.2.14) between the publication of the Offer Document and the end of the Acceptance Period.
–
As further specified in Sections 12.4(a) and (b), the number of QIAGEN Shares (as defined in Section 8.3(i)(A)) issued and outstanding (including outstanding Fractional QIAGEN Shares (as defined in Section 4), with twenty-seven (27) Fractional QIAGEN Shares counted as one (1) QIAGEN Share) not exceeding 230,253,368 at the end of the Acceptance Period, and between the publication of the Offer Document and the end of the Acceptance Period, (i) no QIAGEN Shares have been issued and no subscription rights, options, (convertible) bonds or other financial instruments granting a right to receive QIAGEN Shares have been granted by QIAGEN to a third party (other than Thermo Fisher, the Bidder Top Up Affiliate (as defined in Section 8.3(i)) or the Bidder), other than pursuant to (x) QIAGEN Equity Plans (as defined in Section 7.2.3) or (y) QIAGEN Warrants, and (ii) QIAGEN or its legal representatives have neither publicly announced nor notified Thermo Fisher or the Bidder, nor has the Bidder or Thermo
|
|
| | | |
Fisher otherwise obtained knowledge, that any of the events mentioned in the preceding clause (i) has occurred.
|
|
| | | |
–
As further specified in Section 12.4(c), the general meeting of QIAGEN not adopting any resolutions, other than the Resolutions (as defined in Section 8.3), regarding any increase of the share capital, split of QIAGEN Shares, consolidation of QIAGEN Shares, change of rights pertaining to, or the nature of, QIAGEN Shares or amendment of the articles of association of QIAGEN between the publication of the Offer Document and the end of the Acceptance Period.
–
As further specified in Section 12.5, the general meeting of QIAGEN having adopted the Back-End Resolution (as defined in Section 8.3(i)) between the publication of the Offer Document and the end of the Acceptance Period.
–
As further specified in Section 12.6, no Order (as defined in Section 12.6), stay, judgment or decree having been issued by any Governmental Authority (as defined in Section 8.2.15) of competent jurisdiction that remains in force and effect immediately before the end of the Acceptance Period, and no statute, rule, regulation or other law of any Governmental Authority of competent jurisdiction having been enacted that remains in force and effect immediately before the end of the Acceptance Period, which in any case prohibits the completion of the Offer or the other Transactions (as defined in Section 4), in whole or in part, in accordance with the Business Combination Agreement.
–
As further specified in Section 12.7, between the publication of the Offer Document and the end of the Acceptance Period, (i) QIAGEN not being subject to a voluntary or involuntary liquidation, administration order, suspension of payments or any other insolvency proceeding in any jurisdiction and (ii) QIAGEN or its legal representatives not having publicly announced nor notified Thermo Fisher or the Bidder, nor have the Bidder or Thermo Fisher otherwise obtained knowledge, that any of the events mentioned in the preceding clause (i) has occurred.
–
As further specified in Section 12.8, no Material Adverse Effect (as defined in Section 12.8) having occurred between the publication of the Offer Document and the end of the Acceptance Period.
–
As further specified in Section 12.9, no Material Compliance Violation (as defined in Section 12.9) having occurred between the publication of the Offer Document and the end of the Acceptance Period.
The Bidder will seek to complete the merger control procedures (see Sections 11.1 and 11.2) by July 27, 2021 (the “Long Stop Date”).
|
|
| | | | If one or more of the Offer Conditions (as defined in Section 12) have not been timely satisfied and the Bidder did not previously effectively waive such condition, the Offer will lapse and the agreements which have been entered into as a result of the acceptance of the Offer will cease to exist and will not be consummated (conditions subsequent within the meaning of German law (auflösende Bedingungen)). | |
| | | | In the Business Combination Agreement, Thermo Fisher and QIAGEN agreed that the Bidder may waive the Offer Conditions specified in Section 12.1, Section 12.3 (with respect to an Adverse Recommendation Change in relation to a Competing Offer) and Section 12.6, only with the written consent of QIAGEN. | |
|
ISIN/CUSIP:
|
| |
QIAGEN Shares:
ISIN NL0012169213; CUSIP N72482123.
Tendered Clearstream Shares (as defined in Section 13.1.3(a)(i)): ISIN NL0014676538
|
|
|
Acceptance of the Offer for Clearstream Shares:
|
| |
Acceptance of the Offer by holders of QIAGEN Shares that are held in the Clearstream system must be declared in writing or in text by the relevant QIAGEN Shareholder to the Custodian Bank (as defined in Section 13.1.2) during the Acceptance Period or Additional Acceptance Period.
Until the Settlement pursuant to the terms and conditions of this Offer Document, the Clearstream Shares (as defined in Section 13) for which acceptance of the Offer has become effective will remain in the accepting QIAGEN Shareholder’s securities account. However, they will each be rebooked under a different ISIN and therefore identified as tendered QIAGEN Shares.
As described in more detail in Section 13.1, the acceptance of the relevant QIAGEN Shareholder will only become effective upon the QIAGEN Shares for which the Offer has been accepted being rebooked, in due time, at Clearstream under ISIN NL0014676538.
|
|
|
Acceptance of the Offer for DTC Shares:
|
| | Acceptance of the Offer by holders of DTC Shares (as defined in Section 13) must be declared to the Settlement Agent using one of the procedures described in Section 13.2. | |
|
Costs of Acceptance:
|
| |
The Settlement will be free of costs and expenses (except for costs incurred for transmitting a declaration of acceptance or letter of transmittal, as applicable, to a Custodian Bank or the Settlement Agent, as applicable) for QIAGEN Shareholders who hold their QIAGEN Shares in the Clearstream system in a securities deposit account with a Custodian Bank in Germany or whose ownership of QIAGEN Shares is directly registered on the QIAGEN shareholders register, including QIAGEN Shares that are held in book-entry form on the books of QIAGEN’s transfer agent.
Shareholders who hold their QIAGEN Shares in the Depository Trust Company system through a broker or other securities intermediary and whose broker or other securities intermediary accepts the Offer on the shareholder’s behalf may be charged a fee.
|
|
| | | | Any non-German exchange tax, sales tax or stamp tax resulting from the acceptance of the Offer shall be borne by QIAGEN Shareholders. See Sections 13.1.7 and 13.2.6 for additional information regarding the costs of acceptance. | |
|
Right of Withdrawal:
|
| | QIAGEN Shareholders who accept the Offer during the Acceptance Period may withdraw their declared acceptance in respect of their QIAGEN Shares at any time until the end of the Acceptance Period, without having to give any reason. QIAGEN Shareholders who have exercised their right of withdrawal may re-accept the Offer prior to the end of the Additional Acceptance Period as described in this Offer Document. | |
| | | |
In addition to the aforementioned withdrawal rights, the following statutory withdrawal rights exist prior to the end of the Acceptance Period:
–
In the event of an amendment of the Offer pursuant to Sec. 21 para. 1 WpÜG, QIAGEN Shareholders may, at any time until the end of the Acceptance Period, withdraw from the contracts entered into as a result of acceptance of the Offer if and to the extent that they have accepted the Offer prior to the publication of the amendment of the Offer (pursuant to Sec. 21 para. 4 WpÜG); and
|
|
| | | |
–
In the event of a competing offer pursuant to Sec. 22 para. 1 WpÜG, QIAGEN Shareholders may, at any time until the end of the Acceptance Period, withdraw from the contracts entered into as a result of acceptance of the Offer if and to the extent that they have accepted the Offer prior to publication of the offer document for the competing offer (Sec. 22 para. 3 WpÜG).
QIAGEN Shareholders will have no withdrawal rights for the forty-five (45)-calendar day period following the end of the Acceptance Period, even if the Offer condition described in Section 12.2 has not yet been satisfied or previously effectively waived and the Bidder has, accordingly, not yet become obligated to pay the Offer Price. As described in Section 17.1, the Bidder may request further relief from the Staff of the SEC to extend this forty-five (45)-calendar day period. If any such extension of the forty-five (45)-calendar day period is granted, the Bidder will promptly notify QIAGEN Shareholders in accordance with procedures described in Section 20.
Although tendered QIAGEN Shares may not be withdrawn for the forty-five (45)-calendar day period (as it may be extended as described in Section 17.1) following the end of the Acceptance Period, Tendered Clearstream Shares will be eligible to trade on the regulated market of the FSE (Prime Standard) under ISIN NL0014676538 under certain circumstances as described in Section 13.1.8.
Only QIAGEN Shareholders who hold Clearstream Shares may trade tendered QIAGEN Shares on the regulated market of the FSE as described in Section 13.1.8. Trading on the regulated “as-tendered” market of the FSE is expected to start on the third (3rd) Banking Day after commencement of the Acceptance Period and end at the close of FSE trading on the day on which a publication is made that all Offer Conditions have been met or effectively waived.
|
|
| | | |
There will be no stock market trading of DTC Shares or Directly Registered Shares that have been tendered into the Offer. There may be a lengthy period of time between the deadline for tendering QIAGEN Shares into the Offer and the Settlement, which is currently expected to occur in the first half of 2021. QIAGEN Shareholders will not have withdrawal rights for the forty-five (45)-calendar day period following the end of the Acceptance Period, even if the Antitrust Clearance Condition has not yet been satisfied or previously effectively waived and, therefore, the Bidder has not yet become obligated to pay the Offer Price. In addition, as described in Section 17.1, the Bidder may request one or more extensions of this forty-five (45)-calendar day period from the Staff of the SEC. If granted, tendering QIAGEN Shareholders may not have the right to withdraw their QIAGEN Shares for the entire period between the end of the Acceptance Period and the Settlement of the Offer, which may not occur until August 5, 2021. QIAGEN Shareholders who hold Directly Registered Shares or who hold their QIAGEN Shares in the Depository Trust Company system and who wish to have the ability to trade tendered QIAGEN Shares on the regulated “as-tendered” market of the FSE should promptly contact their bank, broker, dealer or other nominee to effect a transfer of such QIAGEN Shares from the Depository Trust Company system or transfer agent, as applicable, to the Clearstream system prior to tendering their QIAGEN Shares into the Offer. The deadline for tendering QIAGEN Shares into the Offer is the end of the Acceptance Period or the Additional Acceptance Period, as applicable. QIAGEN Shareholders who hold Directly Registered Shares or who hold their QIAGEN Shares in the Depository Trust Company system are advised to allow sufficient time for the transfer of their QIAGEN Shares to the Clearstream system.
Additional information regarding rights of withdrawal is included in Section 17.
|
|
|
Publications:
|
| |
The German language version of this Offer Document, the publication of which was permitted by BaFin on May 15, 2020, was published on May 18, 2020, by way of (i) announcement on the Internet at http://corporate.thermofisher.com/en/offer.html?lang=de and (ii) making copies of this Offer Document available free of charge at D.F. King Ltd, Mergenthaler Allee 15-21, 65760 Eschborn, Germany (inquiries via email to QGEN@dfking.com, via fax to +49 69 2222 129 19 or via phone to +49 800 186 0230, indicating a valid mailing address).
The announcement about making copies of this Offer Document available free of charge in Germany and the Internet address at which the publication of the German language version Offer Document is available has been published on May 18, 2020 in the Federal Gazette (Bundesanzeiger).
All notices and announcements required under the WpÜG are published on the Internet at http://corporate.thermofisher.com/en/offer.html. Notices and announcements according to the WpÜG are also published in the Federal Gazette (Bundesanzeiger).
In the United States, the corresponding announcement about making copies of the English language version of the Offer Document available free of charge will be published in The Wall Street Journal. Furthermore, the English language version of this Offer Document
|
|
| | | |
will be published by way of announcement on the Internet at http://corporate.thermofisher.com/en/offer.html and is available in the United States at D.F. King & Co., Inc., 48 Wall Street, 22nd Floor, New York, NY 10005, United States, email: QGEN@dfking.com, and by calling + 1 (877) 297-1744 (toll-free in the United States) for distribution free of charge.
To the extent legally required or at the Bidder’s sole discretion, all notifications and announcements will be published in the United States as part of a press release.
In addition, the Schedule TO that the Bidder and Thermo Fisher have filed with the SEC, of which this Offer Document forms a part, exhibits to the Schedule TO and other information that the Bidder has filed electronically with the SEC may be obtained free of charge at the SEC’s website at http://www.sec.gov.
|
|
|
Settlement:
|
| | The payment of the Offer Price in exchange for QIAGEN Shares validly tendered and not properly withdrawn (the “Settlement”) will be made without undue delay following, but in any event within seven (7) German Business Days following, the later of the end of the Additional Acceptance Period or the satisfaction of the Antitrust Clearance Condition, if the Antitrust Clearance Condition has not been previously effectively waived by the Bidder. | |
| | | |
In the event of the latest possible fulfillment of the Antitrust Clearance Condition (i.e., fulfillment on the Long Stop Date), the Settlement may be delayed until August 5, 2021 (the time that the Bidder accepts for exchange, and exchanges and pays the Offer Price for, all of the QIAGEN Shares validly tendered and not properly withdrawn, the “Settlement Date”).
The payment of the Offer Price (as defined in Section 4) for the Tendered Clearstream Shares will be made to the account of the relevant Custodian Bank with Clearstream simultaneously with the transfer of the Tendered Clearstream Shares to the Bidder (Zug um Zug gegen).
Upon crediting the Offer Price to the respective Custodian Bank’s cash account with Clearstream, the Bidder will have fulfilled its obligation to pay the Offer Price with respect to the Clearstream Shares. It is the respective Custodian Bank’s responsibility to transfer the Offer Price to QIAGEN Shareholders.
The payment of the Offer Price for DTC Shares and Directly Registered Shares, in each case that have been properly tendered and not validly withdrawn, will be made to the account of the Settlement Agent without undue delay, which will transfer the Offer Price to the applicable QIAGEN Shareholders.
|
|
|
Post-Offer Measures:
|
| | Thermo Fisher’s willingness to enter into the Business Combination Agreement and agree to the Offer (including the Offer Price) was predicated on the acquisition of 100% of the QIAGEN Shares or the entirety of QIAGEN’s assets and operations. In light thereof, and the willingness of Thermo Fisher and the Bidder to have a minimum acceptance threshold of less than 95%, QIAGEN and Thermo Fisher have agreed to certain Post-Offer Measures (as defined in Section 8.5.2) in respect of QIAGEN and its subsidiaries (the “QIAGEN Group”). | |
| | | |
Following the Settlement, Thermo Fisher intends to implement or cause to be implemented, if deemed necessary or otherwise appropriate by Thermo Fisher one or more Post-Offer Measures in order to complete its acquisition of QIAGEN’s business, operations and assets. These may include the implementation of the Merger and Liquidation, the Asset Sale and Liquidation or one or more Other Post-Offer Measures, as described in more detail in Section 8.5.
To allow for Thermo Fisher to complete its acquisition of QIAGEN’s business, operations and assets in an optimal manner for U.S. tax purposes, an Affiliate of Thermo Fisher and the Bidder will be granted a Top Up Option (as defined in Section 8.3(i)(A)) to subscribe to a new issue of QIAGEN Ordinary Shares. The Top Up Option, if exercised in full, ensures that Thermo Fisher and its Affiliates hold more than 80% of the voting rights and fair market value of QIAGEN’s share capital on the Settlement Date, prior to completion of the Share Transfer (as defined in Section 8.5.6) or Asset Sale (as defined in Section 8.5.7). Following exercise of the Top Up Option, Thermo Fisher must proceed with the Merger and Liquidation or the Asset Sale and Liquidation, as the case may be.
Thermo Fisher will continue to review the structural, tax, and other implications associated with the implementation of Post-Offer Measures as well as the availability of each such measure under applicable law.
As described in detail in Section 19, the withholding taxes and other taxes, if any, imposed on a non-tendering QIAGEN Shareholder in respect of any advance liquidation distributions and any final liquidation distribution in connection with the Liquidation (as defined in Section 8.5.8) (together, the “Liquidation Distribution”) may be different from, and greater than, the taxes imposed upon such QIAGEN Shareholder had it tendered its QIAGEN Shares pursuant to the Offer. If the Merger and Liquidation or the Asset Sale and Liquidation is pursued, the net amount received by a QIAGEN Shareholder for QIAGEN Shares that are not tendered under the Offer (and who remains a QIAGEN Shareholder up to and including the time of the Asset Sale and Liquidation or the Merger and Liquidation) will depend upon such shareholder’s individual tax circumstances and the amount of any applicable withholding or other taxes.
|
|
| | | | As described in more detail in Section 16(c), QIAGEN Shareholders who do not accept the Offer should be aware that, if the Settlement occurs, non-tendering QIAGEN Shareholders will not be able to prevent the implementation of one or more Post-Offer Measures. In addition, as described in Section 16, tendering QIAGEN Shareholders will be paid earlier than non-tendering QIAGEN Shareholders that receive payment in connection with any subsequent Post-Offer Measure. | |
|
Certain U.S. Federal Income Tax Consequences:
|
| | The receipt of cash in respect of QIAGEN Shares pursuant to the Offer or, if implemented, the Liquidation or the Compulsory Acquisition (or, if the Merger has occurred, in respect of QIAGEN Newco Shares (as defined in Section 8.5.4)) generally will be a taxable transaction for U.S. federal income tax purposes and may also be a taxable transaction under applicable state, local or non-U.S. income or other tax laws. | |
| | | |
All QIAGEN Shareholders are urged to consult their own tax advisors as to the particular tax consequences to them of the Offer and, if implemented, the Merger and Liquidation, the Asset Sale and Liquidation, the Compulsory Acquisition or any Other Post-Offer Measure.
See Section 19.1 for a more detailed discussion of the material U.S. federal income tax consequences for tendering and non-tendering QIAGEN Shareholders.
|
|
|
Certain Dutch Tax Consequences:
|
| | The receipt of cash in respect of QIAGEN Shares pursuant to the Offer or, if implemented, the Liquidation or the Compulsory Acquisition (or, if the Merger has occurred, in respect of QIAGEN Newco Shares) generally will be a taxable transaction for Dutch income tax purposes and may also be a taxable transaction under applicable non-Dutch tax laws. | |
| | | |
If Thermo Fisher elects to effect the Merger and Liquidation or the Asset Sale and Liquidation, the Liquidation Distribution to be ultimately received by the non-tendering QIAGEN Shareholders is generally subject to a 15% Dutch dividend withholding tax to the extent that the Liquidation Distribution exceeds the average paid up capital recognized for Dutch dividend withholding tax purposes (which QIAGEN expects to be the case), while the payment of the Offer Price to tendering QIAGEN Shareholders will generally not be subject to Dutch withholding taxes. Hence, the cash payment to be received by non-tendering QIAGEN Shareholders may be less than they would have received in the event they had tendered their QIAGEN Shares in the Offer.
All QIAGEN Shareholders are urged to consult their own tax advisors as to the particular tax consequences to them of the Offer and, if implemented, the Merger and Liquidation, the Asset Sale and Liquidation, the Compulsory Acquisition or any Other Post-Offer Measure, including any Dutch withholding tax consequences.
See Section 19.2 for a more detailed discussion of material Dutch tax consequences for tendering and non-tendering QIAGEN Shareholders.
|
|
|
Certain German Tax Consequences:
|
| |
The receipt of cash in respect of QIAGEN Shares pursuant to the Offer or, if implemented, the Liquidation or the Compulsory Acquisition (or, if the Merger has occurred, in respect of QIAGEN Newco Shares) will generally be a taxable transaction for German income tax purposes and may also be a taxable transaction under applicable non-German tax laws. If Thermo Fisher elects to effect the Merger and Liquidation, the exchange of QIAGEN Shares against QIAGEN Newco Shares due to the Merger might constitute a taxable event for certain groups of non-tendering QIAGEN Shareholders under German tax laws. Also, if Thermo Fisher elects to effect the Merger and Liquidation or the Asset Sale and Liquidation, the taxation of the Liquidation Distribution to be ultimately received by non-tendering QIAGEN Shareholders might differ from the taxation of the cash amount they would have received in the event they had tendered their QIAGEN Shares in the Offer.
All QIAGEN Shareholders are urged to consult their own tax advisors as to the particular tax consequences to them of the Offer and, if
|
|
| | | | implemented, the Merger and Liquidation, the Asset Sale and Liquidation, the Compulsory Acquisition or any Other Post-Offer Measure. | |
| | | | See Section 19.3 for a more detailed discussion of material German tax consequences for tendering and non-tendering QIAGEN Shareholders. | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
Marc N. Casper | | | United States | | | Mr. Casper, age 52, has been President and Chief Executive Officer since October 2009, and was also elected Chairman of Thermo Fisher’s board in February 2020. He served as Thermo Fisher’s Executive Vice President and Chief Operating Officer from 2008 to 2009, and as Executive Vice President and President, Analytical Technologies, from 2006 to 2008. Prior to that, he was Senior Vice President from 2003 to 2006, and in 2005 assumed responsibility for all of Thermo Fisher’s operating divisions. He joined Thermo Fisher in 2001 as President of the Life Sciences sector of Thermo Electron. He serves on the boards of trustees of Brigham & Women’s Hospital and Wesleyan University and the board of U.S. Bancorp. | |
Mark P. Stevenson | | |
United States,
United Kingdom |
| | Mr. Stevenson, age 57, has been Executive Vice President and Chief Operating Officer of Thermo Fisher since August 2017 and has responsibility for Thermo Fisher’s life sciences, analytical instruments, laboratory products and specialty diagnostics businesses as well as Thermo Fisher’s innovation and digital strategy. He joined Thermo Fisher as Executive Vice President and President, Life Sciences Solutions, through the acquisition of Life Technologies in 2014. He serves on the board of the Personalized Medicine Coalition. | |
Michel Lagarde | | | United States | | | Mr. Lagarde, age 46, was named Executive Vice President in September 2019, with responsibility for Thermo Fisher’s pharma services and customer channels businesses, as well as Thermo Fisher’s corporate accounts function. He joined Thermo Fisher as President, Pharma Services, through the acquisition of Patheon in 2017. Mr. Lagarde previously served as President and Chief Operating officer of Patheon from 2016 to 2017, and | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
| | | | | | prior to that, he was Managing Director at JLL Partners, a leading middle-market private equity firm focused on healthcare, from 2008 to 2016. | |
Michael A. Boxer | | | United States | | | Mr. Boxer, age 58, joined Thermo Fisher in January 2018 as Senior Vice President and General Counsel. Prior to joining Thermo Fisher, Mr. Boxer spent more than 20 years at Luxottica, where he held a number of senior business and legal roles and ultimately became Executive Vice President and Group General Counsel. | |
Syed A. Jafry | | | United States | | | Mr. Jafry, age 56, has served as Senior Vice President and President, Regions since 2017. Prior to that, he was Senior Vice President and President, Asia-Pacific and Emerging Markets from 2011 to 2017. Mr. Jafry serves on the board of directors of Zimmer Biomet. | |
Stephen Williamson
|
| | United States | | | Mr. Williamson, age 53, was named Senior Vice President and Chief Financial Officer, responsible for Thermo Fisher’s tax, treasury, financial reporting and investor relations functions in 2015. In 2008, he became Vice President of Financial Operations for Thermo Fisher and led the finance support function for all of the company’s businesses. He joined Thermo Fisher in 2001 as Vice President, European Financial Operations, based in the U.K. Mr. Williamson serves on the board of International Flavors and Fragrances Inc. | |
Peter E. Hornstra | | | United States | | | Mr. Hornstra, age 60, was appointed Vice President of Thermo Fisher in February 2007 and Chief Accounting Officer in January 2001. He was Corporate Controller from January 1996 to February 2007. | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
Marc N. Casper | | |
United States
|
| | Mr. Casper, age 52, has been President and Chief Executive Officer since October 2009, and was also elected Chairman of Thermo Fisher’s board in February 2020. He served as Thermo Fisher’s Executive Vice President and Chief Operating Officer from 2008 to 2009, and as Executive Vice President and President, Analytical Technologies, from 2006 to 2008. Prior to that, he was Senior Vice President from 2003 to 2006, and in 2005 assumed responsibility for all of Thermo Fisher’s operating divisions. He joined Thermo Fisher in 2001 as President of the Life Sciences sector of Thermo Electron. He serves on the boards of trustees of Brigham & Women’s Hospital and Wesleyan University and the board of U.S. Bancorp. | |
Thomas J. Lynch | | |
United States
|
| | Mr. Lynch, age 65, has been Lead Director since February 2020 and a director of Thermo Fisher since May 2009. He is currently Chairman of the Board of TE Connectivity Ltd. (formerly Tyco Electronics Ltd.), where he previously served as Executive Chairman and Chief Executive Officer. Prior to that, Mr. Lynch | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
| | | | | | was Chief Executive Officer and President of Tyco Engineered Products & Services. He previously served as Executive Vice President of Motorola and President and Chief Executive Officer of Motorola’s Personal Communications sector. Mr. Lynch is currently a director of Automated Data Processing Inc. and Cummins Inc. | |
Nelson J. Chai | | |
United States
|
| | Mr. Chai, age 54, has been a director of Thermo Fisher since December 2010. Since 2018, he has served as Chief Financial Officer of Uber Technologies, Inc., a global ride-hailing technology company. He previously served as the President and Chief Executive Officer of The Warranty Group from 2017 to 2018, and as President of CIT Group, Inc from 2011 to 2015. Mr. Chai also served as Chief Financial Officer of Merrill Lynch & Co., NYSE Euronext, the parent company of the NYSE, and Archipelago Holdings. Mr. Chai is currently a director of the School of Arts and Sciences at the University of Pennsylvania. | |
C. Martin Harris | | |
United States
|
| | Dr. Harris, age 63, has been a director of Thermo Fisher since March 2012. Since 2016, he has served as Associate Vice President of the Health Enterprise and Chief Business Officer of the Dell Medical School at the University of Texas at Austin. Previously, he was Chief Strategy Officer at The Cleveland Clinic Foundation from 2009 to 2016, as well as CIO and Chairman of the Information Technology Division from 1996 to 2016. He also served as a Staff Physician for the Cleveland Clinic Foundation Department of General Internal Medicine from 1996 to 2016. He is currently a director of Invacare Corporation, HealthStream, Inc. and Colgate-Palmolive Company. | |
Tyler Jacks | | |
United States
|
| | Dr. Jacks, age 59, has been a director of Thermo Fisher since May 2009. Since 2001, he has served as the David H. Koch Professor of Biology at the Massachusetts Institute of Technology (“MIT”) and director of the David H. Koch Institute for Integrative Cancer Research. He joined the MIT faculty in 1992. Since 2002, he has also been an investigator with the Howard Hughes Medical Institute, a non-profit medical research organization. Previously he was director of the MIT Center for Cancer Research from 2001 to 2008. He currently serves as a director of Amgen Inc. | |
Judy C. Lewent | | |
United States
|
| | Ms. Lewent, age 71, has been a director of Thermo Fisher since May 2008. From 1990 until her retirement in 2007, she was Chief Financial Officer of Merck & Co., Inc., where she was responsible for worldwide financial, corporate development and licensing matters, as well as for strategic planning. She was also Executive Vice President of Merck from 2001 through her retirement and had additional responsibilities as President of Human Health Asia from 2003 until 2005. She is currently a director of GlaxoSmithKline PLC and Motorola Solutions, Inc. | |
Jim P. Manzi | | |
United States
|
| | Mr. Manzi, age 68, was Chairman of the Board from May 2007 through February 2020 and has been a director of Thermo Fisher since May 2000. Mr. Manzi is the founder and, since 1995, also the | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
| | | | | | Chairman of Stonegate Capital, a firm that manages private equity investment activities in technology startup ventures. From 1984 until 1995, he served as Chairman, President and Chief Executive Officer of Lotus Development Corporation, a software manufacturer that was acquired by IBM Corporation in 1995. He serves as Chairman of the Board and director for Skyword, Inc., and is a director of Cargometrics, Elysium Health, CloverFood Lab, Continental Grain Corp. and Paxos Technology Solutions, LLC. | |
James C. Mullen | | |
United States
|
| | Mr. Mullen, age 61, has been a director of Thermo Fisher since November 2018. He previously served as Chief Executive Officer of Patheon N.V., a leading global provider of pharmaceutical development and manufacturing services from February 2011 until its acquisition by Thermo Fisher in August 2017. From 2000 to 2010, he served as the President and Chief Executive Officer of Biogen Idec, Inc., where he held various operating positions before becoming Chief Executive Officer. Mr. Mullen previously served on the board of directors of Insulet, Inc. and PerkinElmer, Inc. Mr. Mullen is currently a director of Editas Medicine Inc. | |
Lars R. Sørensen | | | Denmark | | | Mr. Sørensen, age 65, has been a director of Thermo Fisher since May 2016. He also served as a director of Thermo Fisher from 2011 to 2015. From 2000 to 2017, Mr. Sørensen was President and Chief Executive Officer of Novo Nordisk A/S, where he previously held several senior management roles. He currently serves as a member of the board of Essity Aktiebologet. | |
Debora L. Spar | | |
United States
|
| | Ms. Spar, age 56, has been a director of Thermo Fisher since September 2019. She is currently the MBA Class of 1952 Professor at Harvard Business School, where she returned after serving as President of Barnard College from 2008 to 2017, and as President and Chief Executive Officer at Lincoln Center for the Performing Arts from 2017 and 2018. Prior to joining Barnard, Ms. Spar was the Spangler Family Professor at Harvard Business School for 17 years and served as Senior Associate Dean for Faculty Research and Development. Ms. Spar currently serves as a director of Value Retail LLC. She is also a member of the American Academy of Arts and Sciences, and trustee of the Howard Hughes Medical Institute, a non-profit medical research organization. She previously served as director of Goldman Sachs until 2017. | |
Scott M. Sperling | | |
United States
|
| | Mr. Sperling, age 62, has been a director of Thermo Fisher since November 2006. Prior to the merger of Thermo Electron Corporation and Fisher Scientific International Inc., he was a director of Fisher Scientific from 1998 to 2006. Since 1994, Mr. Sperling has been Co-President of Thomas H. Lee Partners, L.P., a leveraged buyout firm. Previously he was managing partner of The Aeneas Group, Inc., the private capital affiliate of Harvard Management Company, as well as a senior consultant with the Boston Consulting Group. He is currently a director of The Madison Square Garden Company and Agiliti Health, Inc. | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
Elaine S. Ullian | | |
United States
|
| | Ms. Ullian, age 72, has been a director of Thermo Fisher since July 2001. From 1996 until her retirement in 2010, she served as President and Chief Executive Officer of Boston Medical Center. She previously served as President and Chief Executive Officer of Boston University Medical Center Hospital and Faulkner Hospital. | |
Dion J. Weisler | | | Australia | | | Mr. Weisler, age 52, has been a director of Thermo Fisher since March 2017. He served as President and Chief Executive Officer of HP Inc. from 2015 to 2019. Prior to that, he served as Hewlett-Packard Co.’s Printing and Personal Systems division’s Executive Vice President from 2013 to 2015 and Senior Vice President from 2012 to 2013. He is currently a director of HP Inc. | |
| | |
QIAGEN RSUs
(in thousands) |
| |
QIAGEN PSUs
(in thousands) |
| |
Weighted Average
Contractual Term (in years) |
| |||||||||
Outstanding
|
| | | | 708.7 | | | | | | 5,018.5 | | | | | | 2.75 | | |
Expected to vest before the end of the Additional Acceptance Period
|
| | | | 34.6 | | | | | | 330.2 | | | | | | 0.10 | | |
| | |
Price of a
QIAGEN Share on FSE in EUR |
| |
Price of a
QIAGEN Share on NYSE in USD |
| ||||||||||||||||||
| | |
High
|
| |
Low
|
| |
High
|
| |
Low
|
| ||||||||||||
Quarterly 2018: | | | | | | | | | | | | | | | | | | | | | | | | | |
First Quarter | | | | | 28.33 | | | | | | 25.42 | | | | | | 34.79 | | | | | | 30.78 | | |
Second Quarter | | | | | 32.36 | | | | | | 25.22 | | | | | | 37.61 | | | | | | 31.10 | | |
Third Quarter | | | | | 34.05 | | | | | | 30.64 | | | | | | 39.45 | | | | | | 35.57 | | |
Fourth Quarter | | | | | 33.05 | | | | | | 29.01 | | | | | | 38.27 | | | | | | 32.33 | | |
Quarterly 2019: | | | | | | | | | | | | | | | | | | | | | | | | | |
First Quarter | | | | | 36.19 | | | | | | 29.19 | | | | | | 40.77 | | | | | | 33.52 | | |
Second Quarter | | | | | 37.03 | | | | | | 31.66 | | | | | | 41.55 | | | | | | 35.61 | | |
Third Quarter | | | | | 36.32 | | | | | | 29.21 | | | | | | 40.93 | | | | | | 32.36 | | |
Fourth Quarter | | | | | 39.19 | | | | | | 22.54 | | | | | | 43.16 | | | | | | 25.04 | | |
Quarterly 2020: | | | | | | | | | | | | | | | | | | | | | | | | | |
First Quarter | | | | | 38.75 | | | | | | 29.55 | | | | | | 42.41 | | | | | | 32.97 | | |
Second Quarter (through May 13, 2020)
|
| | | | 39.80 | | | | | | 36.11 | | | | | | 43.39 | | | | | | 39.05 | | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
Roland Sackers | | | Germany | | | Mr. Sackers, age 51, joined QIAGEN in 1999 as Vice President Finance and has been Chief Financial Officer since 2004. In 2006, Mr. Sackers became a member of the Managing Board. Between 1995 and 1999, he served as an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. In 2019, he joined the supervisory board of Evotec SE and is chairman of the audit committee. He is a former member of the supervisory board and audit committee of IBS AG and a former member of the board of directors of Operon Biotechnologies, Inc. Mr. Sackers is a board member of the industry association BIO Deutschland. He was previously a non-executive director and chair of the audit committee from 2011 to 2018 of Immunodiagnostic Systems Holding PLC (IDS), a leading producer of immunological tests for research and diagnostic applications publicly listed in the United Kingdom. | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
Stéphane Bancel | | | France | | |
Mr. Bancel, age 47, joined the Supervisory Board as well as the Compensation Committee in 2013 and joined the Audit Committee and Science and Technology Committee in 2014. He is Chief Executive Officer of Moderna, Inc., a clinical-stage biotechnology company. Before joining Moderna, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. Prior to bioMérieux, he was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis, Indiana, after having started at Lilly in Great Britain. Before joining Eli Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux while based in Tokyo, Japan.
|
|
Dr. Håkan Björklund
|
| | Sweden | | | Dr. Björklund, age 63, was appointed as a Supervisory Board Member in March 2017 and as Chair of the Supervisory Board in June 2018. He is a member of the Compensation Committee and the Selection and Appointment Committee. Dr. Björklund serves as the Operating Executive at Avista Capital Partners. His previous roles include CEO of the global pharmaceutical company Nycomed, Regional Director at Astra (now AstraZeneca), President of Astra Draco and Operating Executive at Avista Capital Partners. In addition to QIAGEN, he currently serves as Chairman of the Board of Directors of OneMed Top Holding AB and Swedish Orphan Biovitrum AB (Sobi) and as a Member of the Board of Directors of BONESUPPORT AB and Tellacq AB. Dr. Björklund earlier served as Chairman of the Board of Directors of Acino International AG and Lundbeck A/S, and was also a Member of the Board of Directors of several international life science companies, including Alere, Atos, Coloplast and Danisco. | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
Dr. Metin Colpan | | | Germany | | | Dr. Colpan, age 65, has been a member of the Supervisory Board since 2004. He has been a member of the Selection and Appointment Committee since 2015 and has served as Chair of the Science and Technology Committee since 2014. He is a co-founder of QIAGEN and was the Chief Executive Officer and a Managing Director from 1985 through 2003. Dr. Colpan also serves as a Supervisory Board member of CGR GmbH in Mettmann, Germany and Heilpflanzenwohl AG in Baar, Germany. Dr. Colpan previously served as a Supervisory Board member of Ingenium Pharmaceuticals AG, GenPat77 Pharmacogenetics AG, GPC Biotech AG and Morphosys AG, each in Munich, Germany and Qalovis Farmer Automatic Energy GmbH, in Laer, Germany. | |
Dr. Ross L. Levine | | | United States | | | Dr. Levine, age 48, joined the Supervisory Board and its Science and Technology Committee in 2016. He is a physician-scientist focused on researching and treating blood and bone marrow cancers as the Laurence Joseph Dineen Chair in Leukemia Research, the Chief of Molecular Cancer Medicine, and an Attending Physician at Memorial Sloan Kettering Cancer Center, as well as Professor of Medicine at Weill Cornell Medical College. | |
Dr. Elaine Mardis
|
| |
United States
|
| | Dr. Mardis, age 57, joined the Supervisory Board and its Science and Technology Committee in 2014. Dr. Mardis is the Co-Executive Director of the Institute for Genomic Medicine at Nationwide Children’s Hospital in Columbus, OH. She is also Professor of Pediatrics at the Ohio State University College of Medicine. Dr. Mardis is the former Robert E. and Louise F. Dunn Distinguished Professor of Medicine at Washington University School of Medicine in St. Louis, MO, where she was on the faculty for 22 years. Dr. Mardis is a board member of the American Association for Cancer Research, and has scientific advisory roles at Kiadis Pharmaceuticals N.V., PACT Pharma LLC, and Interpreta LLC. | |
Lawrence A. Rosen | | | United States | | | Mr. Rosen, age 62, joined the Supervisory Board in 2013. He has served as the Audit Committee’s Chair since 2014 as well as a member of the Audit Committee since 2013. Mr. Rosen was a member of the Board of Management and Chief Financial Officer of Deutsche Post DHL until September 2016. Holding this position since 2009, Mr. Rosen was in charge of controlling, corporate accounting and reporting, investor relations, corporate finance, corporate internal audit and security, taxes, as well as the group’s global business services. Since 2015, Mr. Rosen has served as a member of the board of Lanxess AG and previously served on the board of Postbank AG from 2009 until 2015. | |
Elizabeth E. Tallett | | | United States | | | Ms. Tallett, age 70, joined the Supervisory Board in 2011. She has served since 2016 as Chair of the Compensation Committee, as well as a member of the Audit Committee and Compensation Committee since 2011. She is a member of the Selection and Appointment Committee. Ms. Tallett was a Principal of Hunter Partners, LLC, a management company | |
Name
|
| |
Citizenship
|
| |
Past and Present Principal Occupation or Employment
|
|
| | | | | | for early to mid-stage pharmaceutical, biotechnology and medical device companies, from 2002 until February 2015. Ms. Tallett continues to consult with early stage health care companies. She is a member of the board of directors of Anthem, Inc. (where she is currently Chair), Principal Financial Group, Inc., and Meredith Corp. She is a former director of Coventry Health Care, Inc. Ms. Tallett was a founding board member of the Biotechnology Council of New Jersey and is Chair of the Trustees of Solebury School in Pennsylvania. | |
In EUR millions (USD millions)
|
| |
Bidder prior to
the Offer |
| |
Changes
resulting from capital increase |
| |
After capital
increase |
| |
Calculated
changes resulting from the Settlement of the Offer |
| |
After the
Settlement of the Offer |
| |||||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Non-current assets
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | € |
8,901 ($9,993) |
| | | | € |
8,901 ($9,993) |
| |
Cash and cash equivalents
|
| | | | 0 | | | | | € |
8,901 ($9,993) |
| | | | € |
8,901 ($9,993) |
| | | | -€ |
8,901 (-$9,993) |
| | | | | 0 | | |
Balance sheet total
|
| | | | 0 | | | | | € |
8,901 ($9,993) |
| | | | € |
8,901 ($9,993) |
| | | | | 0 | | | | | € |
8,901 ($9,993) |
| |
EQUITY AND LIABILITIES | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Equity
|
| | | | 0 | | | | | € |
8,901 ($9,993) |
| | | | € |
8,901 ($9,993) |
| | | | | 0 | | | | | € |
8,901 ($9,993) |
| |
Liabilities
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
Balance sheet total
|
| | | | 0 | | | | | € |
8,901 ($9,993) |
| | | | € |
8,901 ($9,993) |
| | | | | 0 | | | | | € |
8,901 ($9,993) |
| |
| | |
Audited
|
| |
Audited
|
| |
Unaudited
|
| |||||||||||||||
In USD millions (EUR millions)
|
| |
Consolidated
balance sheet Thermo Fisher as at December 31, 2019 |
| |
Consolidated
balance sheet QIAGEN as at December 31, 2019 |
| |
Calculated
changes resulting from the Settlement of the Offer |
| |
Combined
balance sheet after Settlement of the Offer |
| ||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | $2,399 | | | | | | $629 | | | | | | -$8 | | | | | | $3,020 | | |
Cash and cash equivalents
|
| | | | (€2,137) | | | | | | (€560) | | | | | | (-€7) | | | | | | (€2,690) | | |
| | | | | $9,495 | | | | | | $941 | | | | | | | | | | | | $10,436 | | |
Other current assets
|
| | | | (€8,457) | | | | | | (€838) | | | | | | 0 | | | | | | (€9,295) | | |
| | | | | $46,488 | | | | | | $3,666 | | | | | | $7,456 | | | | | | $57,610 | | |
Non-current assets
|
| | | | (€41,407) | | | | | | (€3,265) | | | | | | (€6,640) | | | | | | (€51,312) | | |
| | | | | $58,382 | | | | | | $5,236 | | | | | | $7,448 | | | | | | $71,066 | | |
Total assets
|
| | | | (€52,001) | | | | | | (€4,663) | | | | | | (€6,633) | | | | | | (€63,297) | | |
LIABILITIES AND EQUITY | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | $6,197 | | | | | | $951 | | | | | | $10,385 | | | | | | $17,533 | | |
Total current liabilities
|
| | | | (€5,519) | | | | | | (€847) | | | | | | (€9,250) | | | | | | (€15,616) | | |
| | | | | $22,510 | | | | | | $1,748 | | | | | | | | | | | | $24,258 | | |
Total non-current liabilities
|
| | | | (€20,050) | | | | | | (€1,557) | | | | | | 0 | | | | | | (€21,607) | | |
| | | | | $29,675 | | | | | | $2,537 | | | | | | $-2,937 | | | | | | $29,275 | | |
Total equity
|
| | | | (€26,432) | | | | | | (€2,259) | | | | | | (-€2,615) | | | | | | (€26,074) | | |
| | | | | $58,382 | | | | | | $5,236 | | | | | | $7,448 | | | | | | $71,066 | | |
Total liabilities and equity
|
| | | | (€52,001) | | | | | | (€4,663) | | | | | | (€6,633) | | | | | | (€63,297) | | |
| | |
Audited
|
| |
Audited
|
| |
Unaudited
|
| |||
In USD millions (EUR millions)
|
| |
2019 Thermo Fisher
income statement |
| |
2019 QIAGEN
income statement |
| |
Calculated changes
resulting from the Settlement of the Offer |
| |
Combined income
statement after Settlement of the Offer |
|
Revenues
|
| |
$25,542
(€22,838) |
| |
$1,526
(€1,365) |
| |
$-18
(-€16) |
| |
$27,050
(€24,187) |
|
Net Income/Loss
|
| |
$3,696
(€3,305) |
| |
$-42
(-€37) |
| |
$-608
(-€543) |
| |
$3,046
(€2,725) |
|
| | |
Aggregate No. of
QIAGEN Options (#)(1) |
| |
Resulting
Consideration (USD) (2) |
| |
Resulting
Consideration (EUR) (2) |
| |||||||||
Executive Officers | | | | | | | | | | | | | | | | | | | |
Thierry Bernard
|
| | | | — | | | | | | — | | | | | | — | | |
Roland Sackers
|
| | | | 58,360 | | | | | $ | 1,294,768 | | | | | € | 1,189,716 | | |
Barthold Piening
|
| | | | — | | | | | | — | | | | | | — | | |
Thomas Schweins
|
| | | | — | | | | | | — | | | | | | — | | |
Jonathan Sheldon
|
| | | | — | | | | | | — | | | | | | — | | |
Jean-Pascal Viola
|
| | | | — | | | | | | — | | | | | | — | | |
Stephany Foster
|
| | | | 3,000 | | | | | $ | 69,181 | | | | | € | 63,568 | | |
Supervisory Board Members | | | | | | | | | | | | | | | | | | | |
Håkan Björklund
|
| | | | — | | | | | | — | | | | | | — | | |
Stéphane Bancel
|
| | | | — | | | | | | — | | | | | | — | | |
Metin Colpan
|
| | | | 4,567 | | | | | $ | 104,277 | | | | | € | 95,816 | | |
Ross L. Levine
|
| | | | — | | | | | | — | | | | | | — | | |
Elaine Mardis
|
| | | | — | | | | | | — | | | | | | — | | |
Lawrence A. Rosen
|
| | | | — | | | | | | — | | | | | | — | | |
Elizabeth E. Tallett
|
| | | | 1,563 | | | | | $ | 41,972 | | | | | € | 38,567 | | |
TOTAL
|
| | | | 67,490 | | | | | $ | 1,510,198 | | | | | € | 1,387,667 | | |
| | |
Aggregate
No. of QIAGEN RSUs (#)(1) |
| |
Resulting
Consideration (USD) (2) |
| |
Resulting
Consideration (EUR) (2) |
| |
Aggregate No.
of QIAGEN PSUs (#)(3) |
| |
Resulting
Consideration (USD) (2) |
| |
Resulting
Consideration (EUR) (2) |
| |
Total
Resulting Consideration (USD) (4) |
| |
Total
Resulting Consideration (EUR) (4) |
| ||||||||||||||||||||||||
Executive Officers | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Thierry Bernard
|
| | | | 20,000 | | | | | $ | 848,874 | | | | | € | 780,000 | | | | | | 227,171 | | | | | $ | 9,641,978 | | | | | € | 8,859,669 | | | | | $ | 10,490,852 | | | | | € | 9,639,669 | | |
Roland Sackers
|
| | | | 53,472 | | | | | $ | 2,269,550 | | | | | € | 2,085,408 | | | | | | 641,957 | | | | | $ | 27,247,030 | | | | | € | 25,036,323 | | | | | $ | 29,516,580 | | | | | € | 27,121,731 | | |
Barthold Piening
|
| | | | — | | | | | | — | | | | | | — | | | | | | 69,135 | | | | | $ | 2,934,345 | | | | | € | 2,696,265 | | | | | $ | 2,934,345 | | | | | € | 2,696,265 | | |
Thomas Schweins
|
| | | | 19,534 | | | | | $ | 829,095 | | | | | € | 761,826 | | | | | | 281,570 | | | | | $ | 11,950,873 | | | | | € | 10,981,230 | | | | | $ | 12,779,968 | | | | | € | 11,743,056 | | |
Jonathan Sheldon
|
| | | | — | | | | | | — | | | | | | — | | | | | | 105,000 | | | | | $ | 4,456,589 | | | | | € | 4,095,000 | | | | | $ | 4,456,589 | | | | | € | 4,095,000 | | |
Jean-Pascal Viola
|
| | | | 6,110 | | | | | $ | 259,331 | | | | | € | 238,290 | | | | | | 211,688 | | | | | $ | 8,984,822 | | | | | € | 8,255,832 | | | | | $ | 9,244,153 | | | | | € | 8,494,122 | | |
Stephany Foster
|
| | | | 1,310 | | | | | $ | 55,601 | | | | | € | 51,090 | | | | | | 86,527 | | | | | $ | 3,672,526 | | | | | € | 3,374,553 | | | | | $ | 3,728,127 | | | | | € | 3,425,643 | | |
Supervisory Board Members | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Håkan Björklund
|
| | | | 28,623 | | | | | $ | 1,214,866 | | | | | € | 1,116,297 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 1,214,866 | | | | | € | 1,116,297 | | |
Stéphane Bancel
|
| | | | 41,509 | | | | | $ | 1,761,796 | | | | | € | 1,618,851 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 1,761,796 | | | | | € | 1,618,851 | | |
Metin Colpan
|
| | | | 39,208 | | | | | $ | 1,664,133 | | | | | € | 1,529,112 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 1,664,133 | | | | | € | 1,529,112 | | |
Ross L. Levine
|
| | | | 35,063 | | | | | $ | 1,488,203 | | | | | € | 1,367,457 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 1,488,203 | | | | | € | 1,367,457 | | |
Elaine Mardis
|
| | | | 41,509 | | | | | $ | 1,761,796 | | | | | € | 1,618,851 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 1,761,796 | | | | | € | 1,618,851 | | |
Lawrence A. Rosen
|
| | | | 41,509 | | | | | $ | 1,761,796 | | | | | € | 1,618,851 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 1,761,796 | | | | | € | 1,618,851 | | |
Elizabeth E. Tallett
|
| | | | 38,740 | | | | | $ | 1,644,269 | | | | | € | 1,510,860 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 1,644,269 | | | | | € | 1,510,860 | | |
TOTAL
|
| | | | 366,587 | | | | | $ | 15,559,309 | | | | | € | 14,296,893 | | | | | | 1,623,048 | | | | | $ | 68,888,162 | | | | | € | 63,298,872 | | | | | $ | 84,447,471 | | | | | € | 77,595,765 | | |
| | |
No. of QIAGEN
RSUs Converting into Adjusted RSUs (#) |
| |
No. of QIAGEN
PSUs Converting into Adjusted RSUs (#) |
| |
Total Value
(USD) (1) |
| |
Total Value
(EUR) (1) |
| ||||||||||||
Executive Officers | | | | | | | | | | | | | | | | | | | | | | | | | |
Thierry Bernard
|
| | | | — | | | | | | 120,000 | | | | | $ | 5,093,244 | | | | | € | 4,680,000 | | |
Roland Sackers
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Barthold Piening
|
| | | | — | | | | | | 20,000 | | | | | $ | 848,874 | | | | | € | 780,000 | | |
Thomas Schweins
|
| | | | — | | | | | | 75,000 | | | | | $ | 3,183,278 | | | | | € | 2,925,000 | | |
Jonathan Sheldon
|
| | | | — | | | | | | 35,000 | | | | | $ | 1,485,530 | | | | | € | 1,365,000 | | |
Jean-Pascal Viola
|
| | | | — | | | | | | 35,000 | | | | | $ | 1,485,530 | | | | | € | 1,365,000 | | |
Stephany Foster
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
TOTAL
|
| | | | — | | | | | | 285,000 | | | | | $ | 12,096,455 | | | | | € | 11,115,000 | | |
| | |
Estimated
Salary and Bonus Component of Severance Payments (USD) (1) |
| |
Estimated
Salary and Bonus Component of Severance Payments (EUR) (1) |
| |
Estimated
Transaction Payments (USD) |
| |
Estimated
Transaction Payments (EUR) |
| |
Total
(USD) |
| |
Total
(EUR) |
| ||||||||||||||||||
Executive Officers | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Thierry Bernard
|
| | | $ | 1,375,616 | | | | | € | 1,264,004 | | | | | $ | 1,600,000 | | | | | € | 1,470,183 | | | | | $ | 2,975,616 | | | | | € | 2,734,187 | | |
Roland Sackers
|
| | | $ | 1,851,243 | | | | | € | 1,701,041 | | | | | $ | 2,416,026 | | | | | € | 2,220,000 | | | | | $ | 4,267,269 | | | | | € | 3,921,041 | | |
Barthold Piening
|
| | | $ | 630,732 | | | | | € | 579,557 | | | | | $ | 618,274 | | | | | € | 568,110 | | | | | $ | 1,249,006 | | | | | € | 1,147,667 | | |
Thomas Schweins
|
| | | $ | 756,183 | | | | | € | 694,830 | | | | | $ | 710,442 | | | | | € | 652,800 | | | | | $ | 1,466,625 | | | | | € | 1,347,630 | | |
Jonathan Sheldon (2)
|
| | | $ | 601,296 | | | | | € | 552,509 | | | | | $ | 570,137 | | | | | € | 523,878 | | | | | $ | 1,171,433 | | | | | € | 1,076,387 | | |
Jean-Pascal Viola
|
| | | $ | 440,039 | | | | | € | 404,336 | | | | | $ | 418,266 | | | | | € | 384,330 | | | | | $ | 858,305 | | | | | € | 788,666 | | |
Stephany Foster
|
| | | $ | 613,288 | | | | | € | 563,528 | | | | | $ | 350,000 | | | | | € | 321,602 | | | | | $ | 963,288 | | | | | € | 885,130 | | |
| /s/ Anthony Hugh Smith | |
|
Anthony Hugh Smith
Managing Director (bestuurder) |
|
Name of Company
|
| |
Seat
|
|
236 Perinton Parkway, LLC | | | Albany, New York, USA | |
27 Forge Parkway LLC | | | Dover, Delaware, USA | |
Abgene Inc. | | | Dover, Delaware, USA | |
Abgene Limited | | | Cheshire, United Kingdom | |
ABII 2 Limited | | | Cheshire, United Kingdom | |
ACI Holdings Inc. | | | Albany, New York, USA | |
Acoustic Cytometry Systems, Inc. | | | Dover, Delaware, USA | |
AcroMetrix LLC | | | Sacramento, California, USA | |
Acros Organics BV | | | Geel, Belgium | |
Advanced Biotechnologies Limited | | | Cheshire, United Kingdom | |
Advanced Scientifics International, Inc. | | | Harrisburg, Pennsylvania, USA | |
Advanced Scientifics, Inc. | | | Harrisburg, Pennsylvania, USA | |
Affymetrix Biotech Shanghai Ltd | | | Shanghai, China | |
Affymetrix Japan K.K. | | | Tokyo, Japan | |
Affymetrix UK Ltd | | | Cheshire, United Kingdom | |
Affymetrix, Inc | | | Dover, Delaware, USA | |
Alchematrix LLC | | | Dover, Delaware, USA | |
Alchematrix, Inc. | | | Dover, Delaware, USA | |
Alfa Aesar (China) Chemical Co. Ltd. | | | Shanghai, China | |
Alfa Aesar (Hong Kong) Limited | | | Causeway Bay, Hong Kong | |
Allergon AB | | | Ängelholm, Sweden | |
Ambion, Inc. | | | Dover, Delaware, USA | |
Apogent Denmark ApS | | | Roskilde, Denmark | |
Apogent Finance Company | | | Dover, Delaware, USA | |
Apogent Holding Company | | | Dover, Delaware, USA | |
Apogent Technologies Inc. | | | Madison, Wisconsin, USA | |
Apogent Transition Corp. | | | Dover, Delaware, USA | |
Apogent U.K. Limited | | | Cheshire, United Kingdom | |
Applied Biosystems B.V. | | | Nieuwerkerk aan den IJssel, Netherlands | |
Applied Biosystems de Mexico S. de R.L. de C.V. | | | Mexico City, Mexico | |
Applied Biosystems Finance B.V. | | | Nieuwerkerk aan den IJssel, Netherlands | |
Applied Biosystems International Inc. | | | Dover, Delaware, USA | |
Applied Biosystems Taiwan LLC | | | Dover, Delaware, USA | |
Applied Biosystems Trading (Shanghai) Company Ltd. | | | Shanghai, China | |
Applied Biosystems, LLC | | | Dover, Delaware, USA | |
Applied Scientific Corporation | | | Sacramento, California, USA | |
App-Tek International Pty Ltd | | | Melbourne, Australia | |
ARG Services LLC | | | Dover, Delaware, USA | |
ASPEX Corporation | | | Harrisburg, Pennsylvania, USA | |
Name of Company
|
| |
Seat
|
|
Avances Cientificos de Mexico, S. de R.L. de C.V. | | | Matamoros, Mexico | |
Avocado Research Chemicals Limited | | | Cheshire, United Kingdom | |
B.R.A.H.M.S. Biotech GmbH | | | Hennigsdorf, Germany | |
B.R.A.H.M.S. GmbH | | | Hennigsdorf, Germany | |
B.R.A.H.M.S. UK Ltd | | | Cheshire, United Kingdom | |
BAC B.V. | | | Naarden, Netherlands | |
BAC IP B.V. | | | Naarden, Netherlands | |
Barnstead Thermolyne LLC | | | Dover, Delaware, USA | |
Beijing Phadia Diagnostics Co Ltd | | | Beijing, China | |
Bender MedSystems GmbH | | | Vienna, Austria | |
Bioanalysis Labsystems, S.A. | | | Barcelona, Spain | |
Biochemical Sciences LLC | | | Dover, Delaware, USA | |
BioTrove Corporation | | | Dover, Delaware, USA | |
BioTrove International, Inc. | | | Dover, Delaware, USA | |
BmT GmbH Laborprodukte | | | Meerbusch — Osterath, Germany | |
Bonsai Tecnologies — Sistemas para Biotecnología e Industria, Unipessoal Lda | | | Loures, Portugal | |
Brammer Bio Holding Company, LLC | | | Dover, Delaware, USA | |
Brammer Bio MA, LLC | | | Dover, Delaware, USA | |
Brammer Bio, LLC | | | Dover, Delaware, USA | |
Bumi-Sans Sendirian Berhad | | | Kuala Lumpur, Malaysia | |
CAC Limited | | | Cheshire, United Kingdom | |
Capitol Scientific Products, Inc. | | | Albany, New York, USA | |
Capitol Vial, Inc. | | | Montgomery, Alabama, USA | |
CB Diagnostics AB | | | Uppsala, Sweden | |
CB Diagnostics Holding AB | | | Uppsala, Sweden | |
CB Diagnostics I AB | | | Goteborg, Sweden | |
Cellomics, Inc. | | | Dover, Delaware, USA | |
CellzDirect, Inc. | | | Dover, Delaware, USA | |
CEPH International Corporation | | | San Juan, Puerto Rico, USA | |
Cezanne S.A.S. | | | Nimes, France | |
Chase Scientific Glass, Inc. | | | Madison, Wisconsin, USA | |
CHK Holdings Inc. | | | Dover, Delaware, USA | |
Chromacol Limited | | | Cheshire, United Kingdom | |
Clintrak Clinical Labeling Services, LLC | | | Dover, Delaware, USA | |
Clintrak Pharmaceutical Services, LLC | | | Dover, Delaware, USA | |
Cohesive Technologies (UK) Limited | | | Cheshire, United Kingdom | |
Cohesive Technologies Inc. | | | Dover, Delaware, USA | |
Columbia Diagnostics, Inc. | | | Dover, Delaware, USA | |
Compendia Bioscience, Inc. | | | Canton, Michigan, USA | |
Comtest Limited | | | Cheshire, United Kingdom | |
Consolidated Technologies, Inc. | | | Madison, Wisconsin, USA | |
Consultores Fisher Scientific Chile Ltd | | | Santiago, Chile | |
Name of Company
|
| |
Seat
|
|
Core Informatics UK Ltd. | | | Cheshire, United Kingdom | |
Core Informatics, LLC | | | East Hartford, Connecticut, USA | |
CTPS LLC | | | Dover, Delaware, USA | |
DCG Systems B.V. | | | Amsterdam, Netherlands | |
DCG Systems C.V. | | | Breda, Netherlands | |
DCG Systems G.K. | | | Tokyo, Japan | |
DCG Systems GmbH | | | Munich, Germany | |
DCG Systems Korea Ltd. | | | Seoul, Korea | |
DCG Systems LLC | | | Dover, Delaware, USA | |
D-finitive Technologies, Inc. | | | Charleston, South Carolina, USA | |
Diagnostix Ltd. | | | Toronto, Canada | |
Dionex (Switzerland) AG | | | Reinach, Switzerland | |
Dionex (UK) Limited | | | Cheshire, United Kingdom | |
Dionex Austria GmbH | | | Vienna, Austria | |
Dionex Benelux B.V. | | | Amsterdam, Netherlands | |
Dionex Canada Ltd. | | | Toronto, Canada | |
Dionex China Limited | | | Causeway Bay, Hong Kong | |
Dionex Corporation | | | Dover, Delaware, USA | |
Dionex Denmark A/S | | | Hvidovre, Denmark | |
Dionex Holding GmbH | | | Dreieich, Germany | |
Dionex I, LLC | | | Dover, Delaware, USA | |
Dionex Pty Limited | | | Melbourne, Australia | |
Dionex S.A. | | | Villebon-sur-Yvette, France | |
Dionex S.p.A. | | | Rodano, Italy | |
Dionex Singapore Pte Ltd. | | | Singapore, Singapore | |
Dionex Softron GmbH | | | Germering, Germany | |
Dionex Sweden AB | | | Hägersten, Sweden | |
Distribution Solutions International, Inc. | | | Plymouth, Michigan, USA | |
Doe & Ingalls Investors, Inc. | | | Dover, Delaware, USA | |
Doe & Ingalls Limited | | | Dublin, Ireland | |
Doe & Ingalls Management, LLC | | | Dover, Delaware, USA | |
Doe & Ingalls of California Operating LLC | | | Raleigh, North Carolina, USA | |
Doe & Ingalls of Florida Operating LLC | | | Tallahassee, Florida, USA | |
Doe & Ingalls of Maryland Operating LLC | | | Raleigh, North Carolina, USA | |
Doe & Ingalls of Massachusetts Operating LLC | | | Raleigh, North Carolina, USA | |
Doe & Ingalls of North Carolina Operating LLC | | | Raleigh, North Carolina, USA | |
Doe & Ingalls Properties II, LLC | | | Raleigh, North Carolina, USA | |
Doe & Ingalls Properties, LLC | | | Raleigh, North Carolina, USA | |
Doublecape Holding Limited | | | Cheshire, United Kingdom | |
Doublecape Limited | | | Cheshire, United Kingdom | |
DPI Newco LLC | | | Dover, Delaware, USA | |
Drakeside Real Estate Holding Company LLC | | | Dover, Delaware, USA | |
DSM Pharmaceutical Products, Inc. | | | Dover, Delaware, USA | |
Name of Company
|
| |
Seat
|
|
Duke Scientific Corporation | | | Sacramento, California, USA | |
Dynal Biotech Beijing Limited | | | Beijing, China | |
eBioscience SAS | | | Paris, France | |
eBioscience, Ltd | | | Cheshire, United Kingdom | |
Ecochem N.V. | | | Geel, Belgium | |
EGS Gauging Ltd. | | | Cheshire, United Kingdom | |
EGS Gauging Technical Services Company | | | Dover, Delaware, USA | |
EP Scientific Products LLC | | | Dover, Delaware, USA | |
Epsom Glass Industries Limited | | | Cheshire, United Kingdom | |
Equibio Limited | | | Cheshire, United Kingdom | |
Erie Finance 1 Limited | | | Cheshire, United Kingdom | |
Erie Finance 2 Limited | | | Cheshire, United Kingdom | |
Erie Finance Holding Limited | | | Cheshire, United Kingdom | |
Erie Finance Limited | | | Cheshire, United Kingdom | |
Erie Finance LLC | | | Dover, Delaware, USA | |
Erie LP Holding LLC | | | Dover, Delaware, USA | |
Erie Luxembourg LLC | | | Dover, Delaware, USA | |
Erie N10 LLC | | | Dover, Delaware, USA | |
Erie N2 LLC | | | Dover, Delaware, USA | |
Erie N2 UK Limited | | | Cheshire, United Kingdom | |
Erie Scientific Company of Puerto Rico | | | Dover, Delaware, USA | |
Erie Scientific Hungary Ipari és Szolgáltató Kft | | | Budapest, Hungary | |
Erie Scientific LLC | | | Dover, Delaware, USA | |
Erie U.K. Limited | | | Cheshire, United Kingdom | |
Erie UK 1 Limited | | | Cheshire, United Kingdom | |
Erie UK 1 LLC | | | Dover, Delaware, USA | |
Erie UK 2 Limited | | | Cheshire, United Kingdom | |
Erie UK 3 Limited | | | Cheshire, United Kingdom | |
Erie UK 4 Limited | | | Cheshire, United Kingdom | |
Erie UK 5 Limited | | | Cheshire, United Kingdom | |
Erie UK Holding Company | | | Dover, Delaware, USA | |
Erie UK Senior Holding Limited | | | Cheshire, United Kingdom | |
Erie US II LLC | | | Dover, Delaware, USA | |
Erie US III LLC | | | Dover, Delaware, USA | |
European Laboratory Holdings Limited | | | Dublin, Ireland | |
Eutech Instruments Europe B.V. | | | Nijkerk, Netherlands | |
Eutech Instruments Pte Ltd. | | | Singapore, Singapore | |
Eutech Instruments Sdn Bhd | | | Kuala Lumpur, Malaysia | |
Ever Ready Thermometer Co., Inc. | | | Madison, Wisconsin, USA | |
FB2 Blocker, LLC | | | Dover, Delaware, USA | |
FEI Asia Pacific Co., Ltd. | | | Shanghai, China | |
FEI Australia Pty Ltd | | | Melbourne, Australia | |
FEI Company | | | Salem, Oregon, USA | |
Name of Company
|
| |
Seat
|
|
FEI Company Japan Ltd. | | | Tokyo, Japan | |
FEI Company of USA (S.E.A.) Pte Ltd. | | | Singapore, Singapore | |
FEI CPD B.V. | | | Eindhoven, Netherlands | |
FEI Deutschland GmbH | | | Dreieich, Germany | |
FEI EFA International Pte. Ltd. | | | Singapore, Singapore | |
FEI EFA, Inc. | | | Dover, Delaware, USA | |
FEI Electron Optics B.V. | | | Eindhoven, Netherlands | |
FEI Electron Optics International B.V. | | | Eindhoven, Netherlands | |
FEI Europe B.V. | | | Eindhoven, Netherlands | |
FEI France SAS | | | Villebon-Sur-Yvette, France | |
FEI Global Holdings C.V. | | | Eindhoven, Netherlands | |
FEI Hong Kong Company Limited | | | Causeway Bay, Hong Kong | |
FEI Houston, Inc. | | | Dover, Delaware, USA | |
FEI Italia Srl | | | Milano, Italy | |
FEI Korea Ltd. | | | Gyeonggi-do, Korea | |
FEI Melbourne Pty Ltd. | | | Melbourne, Australia | |
FEI Microscopy Solutions Ltd | | | Kiriyat Sade Hateufa, Israel | |
FEI Norway Holding AS | | | Drammen, Norway | |
FEI SAS | | | Bordeaux, France | |
FEI Saudi Arabia LLC | | | Thuwal, Saudi Arabia | |
FEI Servicos de Nanotecnologia Ltda. | | | Rio de Janeiro, Brazil | |
FEI Technologies, Inc. | | | Salem, Oregon, USA | |
FEI Technology de Mexico S.A. de C.V. | | | Monterrey, Nuevo Leon, Mexico | |
FEI Trading (Shanghai) Co., Ltd. | | | Shanghai, China | |
FEI Trondheim AS | | | Trondheim, Norway | |
FEI UK Ltd. | | | Cheshire, United Kingdom | |
Fermentas China Co., Ltd | | | Shenzhen, China | |
Fermentas Inc. | | | Rockville, Maryland | |
Fermentas Sweden AB | | | Stockholm, Sweden | |
Fermentas UK Limited | | | Cheshire, United Kingdom | |
FHP LLC | | | Dover, Delaware, USA | |
Fiberlite Centrifuge LLC | | | Dover, Delaware, USA | |
Finesse Scientific Equipment (Shanghai) Co., Ltd. | | | Shanghai, China | |
Finesse Solutions AG | | | Reinach, Switzerland | |
Finesse Solutions, Inc. | | | Dover, Delaware, USA | |
Fisher Alder S. de R.L. de C.V. | | | Queretaro, Mexico | |
Fisher Asia Manufacturing Ventures Inc. | | | Tortola, British Virgin Islands | |
Fisher Bermuda Holdings Limited | | | Hamilton, Bermuda | |
Fisher Bioblock Holding II SNC | | | llkirch-Gaffenstaden, France | |
Fisher BioImage ApS | | | Roskilde, Denmark | |
Fisher BioPharma Services (India) Private Limited | | | Ahmedabad, Gujarat, India | |
Fisher BioSciences Japan G.K. | | | Yokohama, Japan | |
Fisher BioServices Inc. | | | Rockville, Virginia, USA | |
Name of Company
|
| |
Seat
|
|
Fisher Canada Holding ULC 1 | | | Halifax, Nova Scotia, Canada | |
Fisher Canada Holding ULC 2 | | | Halifax, Nova Scotia, Canada | |
Fisher Canada Holding ULC 3 | | | Halifax, Nova Scotia, Canada | |
Fisher Canada Limited Partnership | | | New Brunswick, Canada | |
Fisher Clinical Logistics LLC | | | Dover, Delaware, USA | |
Fisher Clinical Services (Beijing) Co., Ltd. | | | Beijing, China | |
Fisher Clinical Services (Bristol), LLC | | | Dover, Delaware, USA | |
Fisher Clinical Services (Colombia) LLC | | | Dover, Delaware, USA | |
Fisher Clinical Services (Korea) Co., Ltd | | | Seoul, Korea | |
Fisher Clinical Services (Mexico) LLC | | | Dover, Delaware, USA | |
Fisher Clinical Services (Peru) LLC | | | Dover, Delaware, USA | |
Fisher Clinical Services (Suzhou) Co., Ltd. | | | Suzhou, China | |
Fisher Clinical Services Colombia S.A.S. | | | Bogota, Colombia | |
Fisher Clinical Services GmbH | | | Allschwil, Switzerland | |
Fisher Clinical Services GmbH | | | Weil am Rhein, Germany | |
Fisher Clinical Services Inc. | | | Harrisburg, Pennsylvania, USA | |
Fisher Clinical Services Japan K.K. | | | Tokyo, Japan | |
Fisher Clinical Services Latin America S.R.L. | | | Buenos Aires, Argentina | |
Fisher Clinical Services Limited Liability Company | | | Podolsk, Moscow Region, Russia | |
Fisher Clinical Services Mexico, S. de R.L. de C.V. | | | Ciudad de México, Mexico | |
Fisher Clinical Services Peru S.R.L | | | Lima, Peru | |
Fisher Clinical Services Pte Ltd. | | | Singapore, Singapore | |
Fisher Clinical Services Rheinfelden GmbH | | | Baden, Germany | |
Fisher Clinical Services U.K. Limited | | | Cheshire, United Kingdom | |
Fisher CLP Holding Limited Partnership | | | New Brunswick, Canada | |
Fisher Emergo B.V. | | | Landsmeer, Netherlands | |
Fisher Germany Holdings GmbH | | | Braunschweig, Germany | |
Fisher Hamilton China Inc. | | | Dover, Delaware, USA | |
Fisher Hamilton Mexico LLC | | | Dover, Delaware, USA | |
Fisher Holdings ApS | | | Roskilde, Denmark | |
Fisher Internet Minority Holdings L.L.C. | | | Dover, Delaware, USA | |
Fisher Luxembourg Danish Holdings SARL | | | Luxembourg, Luxembourg | |
Fisher Manufacturing (Malaysia) Sdn Bhd | | | Kuala Lumpur, Malaysia | |
Fisher Maybridge Holdings Limited | | | Cheshire, United Kingdom | |
Fisher Mexico, S. de R.L. de C.V. | | | Ciudad de Mexico, Mexico | |
Fisher Scientific (Austria) GmbH | | | Wein, Austria | |
Fisher Scientific (Hong Kong) Limited | | | Causeway Bay, Hong Kong | |
Fisher Scientific (M) Sdn Bhd | | | Kuala Lumpur, Malaysia | |
Fisher Scientific (SEA) Pte. Ltd. | | | Singapore, Singapore | |
Fisher Scientific A/S | | | Oslo, Norway | |
Fisher Scientific AG | | | Reinach, Switzerland | |
Fisher Scientific Australia Pty Limited | | | Melbourne, Australia | |
Fisher Scientific Biotech Line ApS | | | Roskilde, Denmark | |
Name of Company
|
| |
Seat
|
|
Fisher Scientific Brazil Inc. | | | Dover, Delaware, USA | |
Fisher Scientific Central America Inc. | | | Dover, Delaware, USA | |
Fisher Scientific Chile Inc. | | | Dover, Delaware, USA | |
Fisher Scientific Colombia Inc. | | | Dover, Delaware, USA | |
Fisher Scientific Company | | | Halifax, Nova Scotia, Canada | |
Fisher Scientific Company L.L.C. | | | Dover, Delaware, USA | |
Fisher Scientific Costa Rica Sociedad de Responsabilidad Limitada | | | Santa Ana, Costa Rica | |
Fisher Scientific de Mexico S.A. | | | Ciudad de Mexico, Mexico | |
Fisher Scientific Europe Holdings B.V. | | | Amsterdam, Netherlands | |
Fisher Scientific Germany Beteiligungs GmbH | | | Schwerte, Germany | |
Fisher Scientific GmbH | | | Schwerte, Germany | |
Fisher Scientific GTF AB | | | Göteborg, Sweden | |
Fisher Scientific Holding Company LLC | | | Dover, Delaware, USA | |
Fisher Scientific Holding HK Limited | | | Causeway Bay, Hong Kong | |
Fisher Scientific Holding U.K., Limited | | | Cheshire, United Kingdom | |
Fisher Scientific Holdings (M) Sdn Bhd | | | Kuala Lumpur, Malaysia | |
Fisher Scientific Holdings (S) Pte Ltd | | | Singapore, Singapore | |
Fisher Scientific International LLC | | | Dover, Delaware, USA | |
Fisher Scientific Investments (Cayman), Ltd. | | | George Town, Cayman Islands | |
Fisher Scientific Ireland Investments Unlimited | | | Dublin, Ireland | |
Fisher Scientific Ireland Limited | | | Dublin, Ireland | |
Fisher Scientific Japan, Ltd. | | | Yokohama, Japan | |
Fisher Scientific Jersey Island Limited | | | St. Heller, Jersey | |
Fisher Scientific Korea Ltd | | | Incheon, Korea | |
Fisher Scientific Latin America Inc. | | | Dover, Delaware, USA | |
Fisher Scientific Luxembourg S.a.r.l. | | | Luxembourg, Luxembourg | |
Fisher Scientific Mexicana, S. de R.L. de C.V. | | | Tlalnepantla, Mexico | |
Fisher Scientific Mexico Inc. | | | Dover, Delaware, USA | |
Fisher Scientific Middle East and Africa Inc. | | | Dover, Delaware, USA | |
Fisher Scientific Norway AS | | | Oslo, Norway | |
Fisher Scientific of the Netherlands B.V. | | | Zoetermeer, Netherlands | |
Fisher Scientific Operating Company | | | Dover, Delaware, USA | |
Fisher Scientific Oxoid Holdings Ltd. | | | Cheshire, United Kingdom | |
Fisher Scientific Oy | | | Vantaa, Finland | |
Fisher Scientific Pte. Ltd. | | | Singapore, Singapore | |
Fisher Scientific S.A.S. | | | D’illkirch-Graffenstaden, France | |
Fisher Scientific S.L. | | | Madrid, Spain | |
Fisher Scientific SPRL | | | Brussels, Belgium | |
Fisher Scientific The Hague I B.V. | | | The Hague, Netherlands | |
Fisher Scientific The Hague II B.V. | | | The Hague, Netherlands | |
Fisher Scientific The Hague III B.V. | | | The Hague, Netherlands | |
Fisher Scientific The Hague IV B.V. | | | The Hague, Netherlands | |
Name of Company
|
| |
Seat
|
|
Fisher Scientific The Hague V B.V. | | | The Hague, Netherlands | |
Fisher Scientific U.K., Limited | | | Cheshire, United Kingdom | |
Fisher Scientific UK Holding Company 2 | | | Cheshire, United Kingdom | |
Fisher Scientific UK Holding Company Limited | | | Cheshire, United Kingdom | |
Fisher Scientific Venezuela Inc. | | | Dover, Delaware, USA | |
Fisher Scientific Worldwide (Shanghai) Co., Ltd. | | | WaiGaoQiao, China | |
Fisher Scientific Worldwide Holdings I C.V. | | | Breda, Netherlands | |
Fisher Scientific Worldwide Inc. | | | Dover, Delaware, USA | |
Fisher Scientific, spol. S.r.o | | | Pardubice, Czech Republic | |
Fisher Scientific, Unipessoal, Lda. | | | Oeiras, Portugal | |
Fisher Servicios Clinicos (Chile) LLC | | | Dover, Delaware, USA | |
Fisher Servicios Clinicos Chile Ltda | | | Santiago, Chile | |
Fisher Worldwide Distribution SPV | | | George Town, Cayman Islands | |
Fisher Worldwide Gene Distribution SPV | | | George Town, Cayman Islands | |
Fisher WWD Holding L.L.C. | | | Dover, Delaware, USA | |
FRC Holding Inc., V | | | Dover, Delaware, USA | |
FS (Barbados) Capital Holdings Ltd. | | | St. Michael, Barbados | |
FS Casa Rocas Holdings LLC | | | Dover, Delaware, USA | |
FS Mexicana Holdings LLC | | | Dover, Delaware, USA | |
FSI Receivables Company LLC | | | Dover, Delaware, USA | |
FSII Sweden Holdings AB | | | Göteborg, Sweden | |
FSII Sweden Holdings I AB | | | Göteborg, Sweden | |
FSII Sweden Holdings II AB | | | Göteborg, Sweden | |
FSIR Holdings (UK) Limited | | | Cheshire, United Kingdom | |
FSIR Holdings (US) Inc. | | | Dover, Delaware, USA | |
FSUK Holdings Limited | | | Cheshire, United Kingdom | |
FSWH Company LLC | | | Dover, Delaware, USA | |
FSWH I LLC | | | Dover, Delaware, USA | |
FSWH II C.V. | | | Breda, Netherlands | |
FSWH II LLC | | | Dover, Delaware, USA | |
FSWH International Holdings LLC | | | Dover, Delaware, USA | |
Fuji Partnership | | | Tokyo, Japan | |
G & M Procter Limited | | | Renfrewshire, Scotland | |
G V Instruments Limited | | | Cheshire, United Kingdom | |
General Scientific Company Sdn Bhd (M) | | | Kuala Lumpur, Malaysia | |
Gold Cattle Standard Testing Labs, Inc. | | | Austin, Texas, USA | |
Golden West Indemnity Company Limited | | | Hamilton, Bermuda | |
Goring Kerr Detection Limited | | | Cheshire, United Kingdom | |
Greenville Service Company, Inc. | | | Dover, Delaware, USA | |
GV Instruments Canada Ltd. | | | Brossard, Quebec, Canada | |
GV Instruments Inc | | | Dover, Delaware, USA | |
Hangar 215, Inc. | | | Dover, Delaware, USA | |
Helmet Securities Limited | | | Cheshire, United Kingdom | |
Name of Company
|
| |
Seat
|
|
HENO GmbH i.L. | | | Berlin, Germany | |
HighChem s.r.o. | | | Bratislava, Slovakia | |
Hybaid Limited | | | Cheshire, United Kingdom | |
HyClone International Trade (Tianjin) Co., Ltd | | | Tianjin, China | |
I.Q. (BIO) Limited | | | Cheshire, United Kingdom | |
IDnostics AG | | | Schlieren, Switzerland | |
ILS Laboratories Scandinavia, AB | | | Uppsala, Sweden | |
Inel Inc. | | | Dover, Delaware, USA | |
Inel SAS | | | Artenay, France | |
InnaPhase Limited | | | Cheshire, United Kingdom | |
InnaPhase, Inc. | | | Toronto, Canada | |
IntegenX Ltd | | | Cheshire, United Kingdom | |
IntegenX, Inc. | | | Sacramento, California, USA | |
Intrinsic BioProbes, Inc. | | | Phoenix, Arizona, USA | |
Invitrogen (Shanghai) Investment Co., Ltd. | | | Shanghai, China | |
Invitrogen Argentina SA | | | Buenos Aires, Argentina | |
Invitrogen BioServices India Private Limited | | | Bangalore, India | |
Invitrogen Europe Limited | | | Renfrewshire, Scotland | |
Invitrogen Finance Corp. | | | Dover, Delaware, USA | |
Invitrogen Holdings LLC | | | Dover, Delaware, USA | |
Invitrogen Holdings Ltd. | | | Renfrewshire, Scotland | |
Invitrogen Hong Kong Limited | | | Causeway Bay, Hong Kong | |
Invitrogen IP Holdings, Inc. | | | Dover, Delaware, USA | |
Invitrogen Trading (Shanghai) Co., Ltd. | | | Shanghai, China | |
Ion Torrent Systems, Inc. | | | Dover, Delaware, USA | |
Jouan Limited | | | Cheshire, United Kingdom | |
Jouan LLC | | | Dover, Delaware, USA | |
JSC “Thermo Fisher Scientific” | | | St. Petersburg, Russia | |
Kendro Containment & Services Limited | | | Cheshire, United Kingdom | |
Kendro Laboratory Products Ltd | | | Cheshire, United Kingdom | |
Kettlebrook Insurance Co. ltd. | | | Honolulu, Hawaii, USA | |
Kyle Jordan Investments LLC | | | Dover, Delaware, USA | |
Lab Vision (UK) Limited | | | Cheshire, United Kingdom | |
Lab-Chrom-Pack LLC | | | Albany, New York, USA | |
Lab-Line Instruments, Inc. | | | Dover, Delaware, USA | |
Labomex MBP, S. de R. L. De C.V. | | | Tijuana, Baja California, Mexico | |
Laboratoire Service International — L.S.I | | | Lissieu, France | |
Laboratory Management Systems, Inc. | | | Dover, Delaware, USA | |
Laboratory Specialties Proprietary Ltd. | | | Gauteng, South Africa | |
LambTrack Limited | | | Cheshire, United Kingdom | |
La-Pha-Pack GmbH | | | Langerwehe, Germany | |
Laser Analytical Systems, Inc. | | | Sacramento, California, USA | |
Liberty Lane Investment LLC | | | Dover, Delaware, USA | |
Name of Company
|
| |
Seat
|
|
Liberty Lane Real Estate Holding Company LLC | | | Dover, Delaware, USA | |
Life Sciences International (Poland) SP z O.O | | | Breda, Netherlands | |
Life Sciences International Holdings B.V. | | | Eindhoven, Netherlands | |
Life Sciences International Limited | | | Cheshire, United Kingdom | |
Life Sciences International LLC | | | Dover, Delaware, USA | |
Life Technologies AS | | | Oslo, Norway | |
Life Technologies Australia PTY Ltd. | | | Melbourne, Australia | |
Life Technologies BPD AB | | | Göteborg, Sweden | |
Life Technologies BPD UK Limited | | | Cheshire, United Kingdom | |
Life Technologies Brasil Comercio e Industria de Produtos para Biotecnologia Ltda | | | Sao Paulo, Brazil | |
Life Technologies Chile SpA | | | Santiago, Chile | |
Life Technologies Clinical Services Lab, Inc. | | | Dover, Delaware, USA | |
Life Technologies Co., Ltd. | | | Taipei City, Taiwan | |
Life Technologies Corporation | | | Dover, Delaware, USA | |
Life Technologies Czech Republic s.r.o | | | Praha, Nové Mesto, Czech Republic | |
Life Technologies DaAn Diagnostic (Guangzhou) Co., Ltd. | | | Guangzhou, China | |
Life Technologies Europe B.V. | | | Nieuwerkerk aan den IJssel, Netherlands | |
Life Technologies Finance Ltd. | | | Renfrewshire, Scotland | |
Life Technologies Finland Oy | | | Helsinki, Finland | |
Life Technologies GmbH | | | Darmstadt, Germany | |
Life Technologies Holdings PTE Ltd. | | | Singapore, Singapore | |
Life Technologies Inc. | | | Burlington, Canada | |
Life Technologies International B.V. | | | Nieuwerkerk aan den IJssel, Netherlands | |
Life Technologies Japan Ltd. | | | Tokyo, Japan | |
Life Technologies Limited | | | Causeway Bay, Hong Kong | |
Life Technologies Limited | | | Renfrewshire, Scotland | |
Life Technologies Magyarorszag Kft | | | Budapest, Hungary | |
Life Technologies New Zealand Ltd. | | | Auckland, New Zealand | |
Life Technologies Norway Investments US LLC | | | Dover, Delaware, USA | |
Life Technologies Polska Sp z.o.o. | | | Warsaw, Poland | |
Life Technologies s.r.o | | | Bratislava, Slovakia | |
Life Technologies SA | | | Madrid, Spain | |
Life Technologies SAS | | | Courtaboeuf, France | |
Linkage Biosciences, Inc. | | | Sacramento, California, USA | |
Linkage Biosciences, S.a.r.l. | | | Plan-les-Ouates, Switzerland | |
Loftus Furnace Company | | | Harrisburg, Pennsylvania, USA | |
Lomb Scientific (Aust) Pty Limited | | | Melbourne, Australia | |
LTC Tech South Africa PTY Ltd. | | | Gauteng, South Africa | |
Marketbase International Limited | | | Causeway Bay, Hong Kong | |
Matrix MicroScience Inc. | | | Dover, Delaware, USA | |
Name of Company
|
| |
Seat
|
|
Matrix MicroScience Ltd. | | | Cheshire, United Kingdom | |
Matrix Technologies Corporation Limited | | | Cheshire, United Kingdom | |
Matrix Technologies LLC | | | Dover, Delaware, USA | |
Maybridge Chemical Company Limited | | | Cheshire, United Kingdom | |
Maybridge Chemical Holdings Limited | | | Cheshire, United Kingdom | |
Maybridge Limited | | | Cheshire, United Kingdom | |
Medical Analysis Systems International, Inc. | | | Sacramento, California, USA | |
Medical Analysis Systems, Inc. | | | Dover, Delaware, USA | |
Medical Diagnostics Systems, Inc. | | | Sacramento, California, USA | |
Metavac LLC | | | Dover, Delaware, USA | |
Microgenics B.V. & Co. KG | | | Hennigsdorf, Germany | |
Microgenics Corporation | | | Dover, Delaware, USA | |
Microgenics Diagnostics Pty Limited | | | Melbourne, Australia | |
Microm Laborgerate S.L. | | | Barcelona, Spain | |
Molecular BioProducts, Inc. | | | Sacramento, California, USA | |
Molecular Probes, Inc. | | | Salem, Oregon, USA | |
Molecular Transfer, Inc. | | | Dover, Delaware, USA | |
Nalge (Europe) Limited | | | Cheshire, United Kingdom | |
Nalge Nunc International (Monterrey) LLC | | | Dover, Delaware, USA | |
Nalge Nunc International Corporation | | | Dover, Delaware, USA | |
Nanjing WeiKangLe Trading Industrial Co Ltd | | | Nanjing, China | |
NanoDrop Technologies LLC | | | Dover, Delaware, USA | |
NAPCO, Inc. | | | East Hartford, Connecticut, USA | |
National Scientific Company | | | Madison, Wisconsin, USA | |
Navaho Acquisition Corp. | | | Dover, Delaware, USA | |
NERL Diagnostics LLC | | | Madison, Wisconsin, USA | |
New FS Holdings Inc. | | | Dover, Delaware, USA | |
NewcoGen PE, LLC | | | Dover, Delaware, USA | |
Nihon Dynal K.K. | | | Tokyo, Japan | |
Niton Asia Limited | | | Causeway Bay, Hong Kong | |
NovaWave Technologies, Inc. | | | Sacramento, California, USA | |
Nunc A/S | | | Roskilde, Denmark | |
Odyssey Holdings Corporation | | | Dover, Delaware, USA | |
Odyssey Holdings LLC | | | Dover, Delaware, USA | |
Odyssey Luxembourg Holdings S.C.S. | | | Luxembourg, Luxembourg | |
Odyssey Luxembourg IP Holdings 1 S.à r.l. | | | Luxembourg, Luxembourg | |
Odyssey Luxembourg IP Holdings 2 S.à r.l. | | | Luxembourg, Luxembourg | |
Odyssey Venture Corporation | | | Dover, Delaware, USA | |
Oncomine Molecular Inc. | | | Dover, Delaware, USA | |
One Lambda, Inc | | | Sacramento, California, USA | |
Onix Holdings Limited | | | Cheshire, United Kingdom | |
ONIX Systems Inc. | | | Dover, Delaware, USA | |
Orme Scientific Limited | | | Cheshire, United Kingdom | |
Name of Company
|
| |
Seat
|
|
Owl Separation Systems LLC | | | Madison, Wisconsin, USA | |
Oxoid (ELY) Limited | | | Cheshire, United Kingdom | |
Oxoid 2000 Limited | | | Cheshire, United Kingdom | |
Oxoid A/S | | | Roskilde, Denmark | |
Oxoid Australia Pty. Limited | | | Melbourne, Australia | |
Oxoid Company | | | Halifax, Nova Scotia, Canada | |
OXOID CZ s.r.o. | | | Brno, Czech Republic | |
Oxoid Deutschland GmbH | | | Wesel, Germany | |
Oxoid Holding SAS | | | Dardilly, France | |
Oxoid Holdings Limited | | | Cheshire, United Kingdom | |
Oxoid Inc. | | | Dover, Delaware, USA | |
Oxoid International Limited | | | Cheshire, United Kingdom | |
Oxoid Investments GmbH | | | Braunschweig, Germany | |
Oxoid Limited | | | Cheshire, United Kingdom | |
Oxoid Limited | | | Dublin Ireland | |
Oxoid N.V. | | | Dilbeek, Belgium | |
Oxoid New Zealand Limited | | | Auckland, New Zealand | |
Oxoid Pension Trustees Limited | | | Cheshire, United Kingdom | |
Oxoid Senior Holdings Limited | | | Cheshire, United Kingdom | |
Oxoid UKH LLC | | | Dover, Delaware, USA | |
Pacific Rim Far East Industries LLC | | | Dover, Delaware, USA | |
Pacific Rim Investment, LLC | | | Dover, Delaware, USA | |
Panomics S.R.L. | | | Pioltello, Italy | |
Panomics, L.L.C. | | | Sacramento, California, USA | |
Pasteur Acquisition SRL | | | Bridgetown, Barbados | |
Pasteur U.S. Corporation | | | Dover, Delaware, USA | |
Patheon API Inc. | | | Columbia, South Carolina, USA | |
Patheon API Manufacturing Inc. | | | Columbia, South Carolina, USA | |
Patheon API Services Inc. | | | Columbia, South Carolina, USA | |
Patheon Austria GmbH & Co. KG | | | Linz, Austria | |
Patheon B.V. | | | Amsterdam, Netherlands | |
Patheon Banner U.S. Holdings Inc. | | | Dover, Delaware, USA | |
Patheon Biologics (NJ) LLC | | | Dover, Delaware, USA | |
Patheon Biologics Australia Pty Ltd | | | Melbourne, Australia | |
Patheon Biologics B.V. | | | Groningen, Netherlands | |
Patheon Biologics LLC | | | Dover, Delaware, USA | |
Patheon Calculus Merger LLC | | | Dover, Delaware, USA | |
Patheon Coöperatief U.A. | | | Amsterdam, Netherlands | |
Patheon Development Services Inc. | | | Dover, Delaware, USA | |
Patheon Finance LLC | | | Dover, Delaware, USA | |
Patheon France SAS | | | Bourgoin-Jallieu, France | |
Patheon Holdings B.V. | | | Amsterdam, Netherlands | |
Patheon Holdings I B.V. | | | Amsterdam, Netherlands | |
Name of Company
|
| |
Seat
|
|
Patheon Holdings II B.V. | | | Amsterdam, Netherlands | |
Patheon Holdings SAS | | | Bourgoin-Jallieu, France | |
Patheon I B.V. | | | Amsterdam, Netherlands | |
Patheon I Holding GmbH | | | Linz, Austria | |
Patheon Inc. | | | Toronto, Canada | |
Patheon International AG | | | Baar, Switzerland | |
Patheon Italia S.p.A. | | | Monza, Italy | |
Patheon KK | | | Tokyo, Japan | |
Patheon Life Science Products International GmbH | | | Linz, Austria | |
Patheon Manufacturing Services LLC | | | Dover, Delaware, USA | |
Patheon Pharmaceuticals Inc. | | | Dover, Delaware, USA | |
Patheon Pharmaceuticals Services Inc. | | | Dover, Delaware, USA | |
Patheon Puerto Rico Acquisitions Corporation | | | San Juan, Puerto Rico, USA | |
Patheon Puerto Rico, Inc. | | | San Juan, Puerto Rico, USA | |
Patheon Regensburg GmbH | | | Regensburg, Germany | |
Patheon Softgels B.V. | | | Tilburg, Netherlands | |
Patheon Softgels Inc. | | | Dover, Delaware, USA | |
Patheon U.S. Holdings Inc. | | | Dover, Delaware, USA | |
Patheon U.S. Holdings LLC | | | Dover, Delaware, USA | |
Patheon UK Limited | | | Cheshire, United Kingdom | |
Patheon UK Pension Trustees Limited | | | Cheshire, United Kingdom | |
PAX — DSI Acquisition LLC | | | Dover, Delaware, USA | |
PE AG | | | Zurich, Switzerland | |
Pelican Acquisition Corporation | | | Dover, Delaware, USA | |
Perbio Science (Canada) Company | | | Halifax, Nova Scotia, Canada | |
Perbio Science AB | | | Göteborg, Sweden | |
Perbio Science BVBA | | | Brussels Belgium | |
Perbio Science France SAS | | | Bourgoin-Jallieu, France | |
Perbio Science International Netherlands B.V. | | | Amsterdam, Netherlands | |
Perbio Science Invest AB | | | Göteborg, Sweden | |
Perbio Science Nederland B.V. | | | Etten-Leur, Netherlands | |
Perbio Science Projekt AB | | | Göteborg, Sweden | |
Perbio Science Sweden Holdings AB | | | Horby, Sweden | |
Perbio Science Switzerland SA | | | Ecublens, Switzerland | |
Perbio Science UK Limited | | | Cheshire, United Kingdom | |
Perbio Science, Inc. | | | Dover, Delaware, USA | |
Percivia LLC | | | Dover, Delaware, USA | |
Phadia AB | | | Uppsala, Sweden | |
Phadia Diagnosticos Ltda | | | Santa Catarina, Brazil | |
Phadia GmbH | | | Freiburg im Breisgau, Germany | |
Phadia Holding AB | | | Uppsala, Sweden | |
Phadia International Holdings C.V. | | | Breda, Netherlands | |
Phadia International LLC | | | Dover, Delaware, USA | |
Name of Company
|
| |
Seat
|
|
Phadia Luxembourg Holdings S.a.r.l. | | | Luxembourg, Luxembourg | |
Phadia Malta Holdings Limited | | | Birkirkara Malta | |
Phadia Real Property AB | | | Uppsala, Sweden | |
Phadia s.r.o. | | | Prague, Czech Republic | |
Phadia Sweden AB | | | Uppsala, Sweden | |
Phadia Taiwan Inc. | | | Taipei City, Taiwan | |
Phadia US Inc. | | | Dover, Delaware, USA | |
Phadia US Market Holdings LLC | | | Dover, Delaware, USA | |
Pharmacaps Mexicana S.A. de C.V. | | | Ciudad de Mexico, Mexico | |
picoSpin, LLC | | | Brighton, Colorado | |
Pierce Biotechnology, Inc. | | | Dover, Delaware, USA | |
Pierce Milwaukee Holding Corp. | | | Dover, Delaware, USA | |
Pierce Milwaukee, Inc. | | | Dover, Delaware, USA | |
Power Sweden Holdings I AB | | | Göteborg, Sweden | |
Power Sweden Holdings II AB | | | Göteborg, Sweden | |
Power Sweden Holdings III Aktiebolag | | | Göteborg, Sweden | |
Princeton Gamma-Tech Instruments LLC | | | Dover, Delaware, USA | |
Prionics AG | | | Schlieren-Zurich, Switzerland | |
Prionics Asia Ltd. | | | Hong Kong Central, Hong Kong | |
Prionics France SAS | | | Villebon-sur-Yvette, France | |
Prionics Italia S.r.l. | | | Milan, Italy | |
Prionics Lelystad B.V. | | | Lelystad, Netherlands | |
Prionics USA Inc. | | | Dover, Delaware, USA | |
Priority Air Express Pte. Ltd. | | | Singapore, Singapore | |
Priority Air Express UK Limited | | | Cheshire, United Kingdom | |
Priority Air Express, LLC | | | Dover, Delaware, USA | |
Priority Air Holdings Corp | | | Dover, Delaware, USA | |
Proxeon Biosystems ApS | | | Roskilde, Denmark | |
Quebec Court B.V. | | | Breda, Netherlands | |
Remel Europe Limited | | | Cheshire, United Kingdom | |
Remel Inc. | | | Madison, Wisconsin, USA | |
REP GBP I-B Blocker, Inc. | | | Dover, Delaware, USA | |
Robbins Scientific LLC | | | Sacramento, California, USA | |
Robocon Labor- und Industrieroboter Gesellschaft m.b.H | | | Wien, Austria | |
Russell pH Limited | | | Renfrewshire, Scotland | |
S.C.I. du 10 rue Dugay Trouin | | | Saint-Herblain, France | |
Samco Scientific (Monterrey) LLC | | | Dover, Delaware, USA | |
Samco Scientific LLC | | | Dover, Delaware, USA | |
Saroph Sweden AB | | | Uppsula, Sweden | |
Schantz Road LLC | | | Harrisburg, Pennsylvania, USA | |
SCI Inno 92 | | | Illkirch-Graffenstaden, France | |
Seradyn Inc. | | | Dover, Delaware, USA | |
Shanghai Life Technologies Biotechnology Co. Limited | | | Shanghai, China | |
Name of Company
|
| |
Seat
|
|
Shanghai Thermo Fisher (C-I) Trading Co. Ltd | | | Shanghai, China | |
Shanghai Thermo Fisher (S) Trading Co. Ltd | | | Shanghai, China | |
Southern Trials (Pty) Ltd. | | | Western Cape, South Africa | |
Specialty (SMI) Inc. | | | Sacramento, California, USA | |
Spectra-Physics AB | | | Uppsala, Sweden | |
Spectra-Physics Holdings Limited | | | Cheshire, United Kingdom | |
Spectra-Physics Holdings USA, LLC | | | Dover, Delaware, USA | |
Staten Island Cogeneration Corporation | | | Albany, New York, USA | |
STC Bio Manufacturing, Inc. | | | Springfield, Illinois, USA | |
Sterilin Limited | | | Cheshire, United Kingdom | |
Stokes Bio Ltd. | | | Dublin, Ireland | |
Sweden DIA (Sweden) AB | | | Uppsala, Sweden | |
SwissAnalytic Group GmbH | | | Reinach, Switzerland | |
Systems Manufacturing Corporation | | | Dover, Delaware, USA | |
Technology Design Solutions Pty Ltd | | | Melbourne, Australia | |
TFLP LLC | | | Dover, Delaware, USA | |
TFS (Barbados) I Srl | | | Bridgetown, Barbados | |
TFS Breda B.V. | | | Breda, Netherlands | |
TFS FEI Holding LLC | | | Dover, Delaware, USA | |
TFS Group Holding I LLC | | | Dover, Delaware, USA | |
TFS Group Holding II LLC | | | Dover, Delaware, USA | |
TFS Life Holding LLC | | | Dover, Delaware, USA | |
TFS LLC | | | Boston, Massachusetts, USA | |
TFS Singapore HK Limited | | | Causeway Bay, Hong Kong | |
TFS Third Avenue (Barbados) I Srl | | | Bridgetown, Barbados | |
TFSL Financing GP LLC | | | Dover, Delaware, USA | |
TFSL Senior GP Holdings 2 LLC | | | Dover, Delaware, USA | |
Thermedics Detection de Argentina S.R.L | | | Buenos Aires, Argentina | |
Thermo Allen Coding Limited | | | Cheshire, United Kingdom | |
Thermo Asset Management Services Inc. | | | Dover, Delaware, USA | |
Thermo BioAnalysis Limited | | | Cheshire, United Kingdom | |
Thermo BioAnalysis LLC | | | Dover, Delaware, USA | |
Thermo BioSciences Holdings LLC | | | Dover, Delaware, USA | |
Thermo Cambridge Limited | | | Cheshire, United Kingdom | |
Thermo Cayman Holdings Ltd. | | | George Town, Cayman Islands | |
Thermo Cayman USC Ltd. | | | George Town, Cayman | |
Thermo CIDTEC Inc. | | | Albany, New York, USA | |
Thermo CN Luxembourg LLC | | | Dover, Delaware, USA | |
Thermo Corporation | | | Dover, Delaware, USA | |
Thermo CRS Holdings Ltd. | | | Toronto, Ontario, Canada | |
Thermo CRS Ltd. | | | Toronto, Ontario, Canada | |
Thermo Detection de Mexico S. de R.L. de C.V. | | | Ciudad de Mexico, Mexico | |
Thermo DMA Inc. | | | Austin, Texas, USA | |
Name of Company
|
| |
Seat
|
|
Thermo Dutch Holdings Limited Partnership | | | George Town, Grand Cayman, Cayman Islands | |
Thermo Eberline Holdings I LLC | | | Dover, Delaware, USA | |
Thermo Eberline Holdings II LLC | | | Dover, Delaware, USA | |
Thermo Eberline LLC | | | Dover, Delaware, USA | |
Thermo EGS Gauging LLC | | | Dover, Delaware, USA | |
Thermo Electron (Calgary) Limited | | | Alberta, Canada | |
Thermo Electron (Chile) S.p.A. | | | Santiago, Chile | |
Thermo Electron (Karlsruhe) GmbH | | | Karlsruhe, Germany | |
Thermo Electron (Management Services) Limited | | | Cheshire, United Kingdom | |
Thermo Electron (Proprietary) Limited | | | Johannesburg, South Africa | |
Thermo Electron A/S | | | Hvidovre, Denmark | |
Thermo Electron Australia Pty Limited | | | Melbourne, Australia | |
Thermo Electron Export Inc. | | | Christ Church, Barbados | |
Thermo Electron Holdings SAS | | | Saint-Herblain, France | |
Thermo Electron Industries | | | Saint-Herblain, France | |
Thermo Electron LED GmbH | | | Langenselbold, Germany | |
Thermo Electron LED GmbH | | | Wein, Austria | |
Thermo Electron LED S.A.S. | | | Saint-Herblain, France | |
Thermo Electron Limited | | | Cheshire, United Kingdom | |
Thermo Electron Manufacturing Limited | | | Cheshire, United Kingdom | |
Thermo Electron Metallurgical Services, Inc. | | | Austin, Texas, USA | |
Thermo Electron North America LLC | | | Dover, Delaware, USA | |
Thermo Electron Pension Trust GmbH | | | Karlsruhe, Germany | |
Thermo Electron Puerto Rico, Inc. | | | San Juan, Puerto Rico, USA | |
Thermo Electron SAS | | | Villebon-sur-Yvette, France | |
Thermo Electron Scientific Instruments LLC | | | Dover, Delaware, USA | |
Thermo Electron Sweden AB | | | Stockholm, Sweden | |
Thermo Electron Sweden Forvaltning AB | | | Uppsala, Sweden | |
Thermo Electron Weighing & Inspection Limited | | | Cheshire, United Kingdom | |
Thermo Elemental Limited | | | Cheshire, United Kingdom | |
Thermo Environmental Instruments LLC | | | Sacramento, California, USA | |
Thermo Fast U.K. Limited | | | Cheshire, United Kingdom | |
Thermo Finland Holdings LLC | | | Dover, Delaware, USA | |
Thermo Finland Holdings MT1 B.V. | | | Amsterdam, Netherlands | |
Thermo Finland Holdings MT2 B.V. | | | Amsterdam, Netherlands | |
Thermo Finnigan Limited | | | Cheshire, United Kingdom | |
Thermo Finnigan LLC | | | Dover, Delaware, USA | |
Thermo Fisher (Cayman) Holdings I Ltd. | | | George Town, Cayman Islands | |
Thermo Fisher (Cayman) Holdings II Ltd. | | | George Town, Cayman Islands | |
Thermo Fisher (CN) Luxembourg Holding S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher (CN) Luxembourg S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher (CN) Malta Holdings Limited | | | Birkirkara, Malta | |
Name of Company
|
| |
Seat
|
|
Thermo Fisher (CN-I) Luxembourg LLC | | | Dover, Delaware, USA | |
Thermo Fisher (CN-II) Luxembourg LLC | | | Dover, Delaware, USA | |
Thermo Fisher (FEI) Ireland Ltd | | | Dublin, Ireland | |
Thermo Fisher (Finland Holdings 2) LLC | | | Dover, Delaware, USA | |
Thermo Fisher (Finland Holdings) Limited Partnership | | | Cheshire, United Kingdom | |
Thermo Fisher (Gibraltar) II Limited | | | Gibraltar, Gibraltar | |
Thermo Fisher (Gibraltar) Limited | | | Gibraltar, Gibraltar | |
Thermo Fisher (Heysham) Limited | | | Cheshire, United Kingdom | |
Thermo Fisher (Kandel) GmbH | | | Karlsruhe, Germany | |
Thermo Fisher Bioprocessing Research and Development (Shanghai) Co., Ltd. | | | Shanghai, China | |
Thermo Fisher China Business Trust | | | Shanghai, China | |
Thermo Fisher China Business Trust II | | | Shanghai, China | |
Thermo Fisher CHK Holding LLC | | | Dover, Delaware, USA | |
Thermo Fisher CM II LLC | | | Dover, Delaware, USA | |
Thermo Fisher Costa Rica Sociedad de Responsabilidad Limitada | | | San Jose, Santa Ana, Costa Rica | |
Thermo Fisher Cyprus Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Detection Mexico LLC | | | Dover, Delaware, USA | |
Thermo Fisher Diagnostics (Ireland) Limited | | | Dublin, Ireland | |
Thermo Fisher Diagnostics AB | | | Göteborg, Sweden | |
Thermo Fisher Diagnostics AG | | | Pratteln, Switzerland | |
Thermo Fisher Diagnostics Aps | | | Allerod, Denmark | |
Thermo Fisher Diagnostics AS | | | Oslo, Norway | |
Thermo Fisher Diagnostics Austria GmbH | | | Wien, Austria | |
Thermo Fisher Diagnostics B.V. | | | Landsmeer, Netherlands | |
Thermo Fisher Diagnostics GmbH | | | Hennigsdorf, Germany | |
Thermo Fisher Diagnostics K.K. | | | Tokyo, Japan | |
Thermo Fisher Diagnostics Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Diagnostics NV | | | Merelbeke, Belgium | |
Thermo Fisher Diagnostics Oy | | | Vantaa, Finland | |
Thermo Fisher Diagnostics S.p.A. | | | Rodano, Italy | |
Thermo Fisher Diagnostics SAS | | | Dardilly, France | |
Thermo Fisher Diagnostics, S.L.U. | | | Cornella de Llobregat, Spain | |
Thermo Fisher Diagnostics, Sociedade Unipessoal Lda | | | Oeiras, Portugal | |
Thermo Fisher Eurobonds Ltd. | | | George Town, Cayman Islands | |
Thermo Fisher Financial Services Inc. | | | Dover, Delaware, USA | |
Thermo Fisher German Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Germany B.V. | | | Breda, Netherlands | |
Thermo Fisher GP LLC | | | Dover, Delaware, USA | |
Thermo Fisher India Holding B.V. | | | Breda, Netherlands | |
Thermo Fisher Insurance Holdings Inc. | | | Dover, Delaware, USA | |
Thermo Fisher Insurance Holdings LLC | | | Dover, Delaware, USA | |
Name of Company
|
| |
Seat
|
|
Thermo Fisher Investments (Cayman) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Investments (Cayman) Ltd. | | | George Town, Cayman Islands | |
Thermo Fisher Israel Ltd. | | | Kiriyat Sade Hateufa, Israel | |
Thermo Fisher Production et Services SAS | | | Morlaas, France | |
Thermo Fisher Project Cyprus LLC | | | Dover, Delaware, USA | |
Thermo Fisher RE I Corporation | | | Dover, Delaware, USA | |
Thermo Fisher RE II Corporation | | | Dover, Delaware, USA | |
Thermo Fisher Re Ltd. | | | Hamilton, Bermuda | |
Thermo Fisher Scientific (Asheville) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (Australia) C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific (Barbados) Holding, Limited | | | Bridgetown, Barbados | |
Thermo Fisher Scientific (Breda) Holding B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific (Bremen) GmbH | | | Bremen, Germany | |
Thermo Fisher Scientific (Cayman) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (China) Co., Ltd. | | | Shanghai, China | |
Thermo Fisher Scientific (China) Holding Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific (China-HK) Holding Limited | | | Causeway Bay, Hong Kong | |
Thermo Fisher Scientific (CN) Limited Partnership | | | Saint John, New Brunswick, Canada | |
Thermo Fisher Scientific (DE) Holding S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific (Ecublens) SARL | | | Ecublens, Switzerland | |
Thermo Fisher Scientific (Finance I) B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific (Finance I) S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific (Finance II) S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific (Finance III) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (Finance III) S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific (Fuji) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (Guangzhou) Co., Ltd | | | Guangzhou, China | |
Thermo Fisher Scientific (Holding II) B.V. & Co. KG | | | Braunschweig, Germany | |
Thermo Fisher Scientific (Hong Kong) Limited | | | Causeway Bay, Hong Kong | |
Thermo Fisher Scientific (IVGN) B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific (IVGN) Limited | | | Causeway Bay, Hong Kong | |
Thermo Fisher Scientific (Johannesburg) (Proprietary) Limited | | | Kempton Park, South Africa | |
Thermo Fisher Scientific (Luxembourg) II S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific (Mexico City) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (Milwaukee) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (Mississauga) Inc. | | | Toronto, Ontario, Canada | |
Thermo Fisher Scientific (Monterrey), S. De R.L. De C.V. | | | Monterrey, Nuevo Leon, Mexico | |
Thermo Fisher Scientific (NK) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (Panama) B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific (Panama) Dutch LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (Panama) II B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific (PN) Austria Holding GmbH | | | Wien, Austria | |
Thermo Fisher Scientific (PN) UK Limited Partnership | | | Cheshire, United Kingdom | |
Name of Company
|
| |
Seat
|
|
Thermo Fisher Scientific (PN) UK LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (PN1) UK Ltd | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific (PN-I) SRL | | | St. Michael, Barbados | |
Thermo Fisher Scientific (PN-II) SRL | | | St. Michael, Barbados | |
Thermo Fisher Scientific (Praha) s.r.o. | | | Prague, Czech Republic | |
Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG | | | Schwerte, Germany | |
Thermo Fisher Scientific (Real Estate 1) S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific (Schweiz) AG | | | Reinach, Switzerland | |
Thermo Fisher Scientific (Shanghai) Instruments Co., Ltd. | | | Shanghai, China | |
Thermo Fisher Scientific (Shanghai) Management Co., Ltd. | | | Shanghai, China | |
Thermo Fisher Scientific (Suzhou) Instruments Co., Ltd | | | Suzhou, China | |
Thermo Fisher Scientific (Thailand) Co., Ltd. | | | Bangkok, Thailand | |
Thermo Fisher Scientific Africa Proprietary Ltd | | | Johannesburg, South Africa | |
Thermo Fisher Scientific AL-1 LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Aquasensors LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Asset Management 1 GmbH | | | Braunschweig, Germany | |
Thermo Fisher Scientific Asset Management 2 GmbH | | | Braunschweig, Germany | |
Thermo Fisher Scientific AU C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific AU II Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific AU Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific AU LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Australia Pty Ltd | | | Melbourne, Australia | |
Thermo Fisher Scientific B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific B.V. | | | Merelbeke, Belgium | |
Thermo Fisher Scientific Baltics UAB | | | Vilnius City, Lithuania | |
Thermo Fisher Scientific Beteiligungsverwaltungs GmbH | | | Braunschweig, Germany | |
Thermo Fisher Scientific BHK (I) Limited | | | Causeway Bay, Hong Kong | |
Thermo Fisher Scientific BHK (II) Limited | | | Causeway Bay, Hong Kong | |
Thermo Fisher Scientific Biosciences Corp. | | | Halifax, Nova Scotia, Canada | |
Thermo Fisher Scientific Brahms LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Brasil Instrumentos de Processo Ltda. | | | Sao Paulo, Brazil | |
Thermo Fisher Scientific Brasil Serviços de Logística Ltda | | | Sao Paulo, Brazil | |
Thermo Fisher Scientific Brno s.r.o. | | | Brno, Czech Republic | |
Thermo Fisher Scientific C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Canada Financing 1 ULC | | | Halifax, Nova Scotia, Canada | |
Thermo Fisher Scientific Canada Financing 2 ULC | | | Halifax, Nova Scotia, Canada | |
Thermo Fisher Scientific Cayman Investments LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Chemicals Inc. | | | Dover, Delaware, USA | |
Thermo Fisher Scientific (China) Analytical Ltd | | | Shanghai, China | |
Thermo Fisher Scientific China (C-I) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific China (S) LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific China Holdings I B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific China Holdings II B.V. | | | Breda, Netherlands | |
Name of Company
|
| |
Seat
|
|
Thermo Fisher Scientific China Holdings III B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific China Holdings IV B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Chromatography Holdings Aps | | | Roskilde, Denmark | |
Thermo Fisher Scientific Chromatography Holdings S.à r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific CMN LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Cork Ltd | | | Dublin, Ireland | |
Thermo Fisher Scientific Cyprus I C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Cyprus I Ltd | | | George Town, Cayman Islands | |
Thermo Fisher Scientific Cyprus II C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Cyprus II Ltd | | | George Town, Cayman Islands | |
Thermo Fisher Scientific Cyprus III C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Cyprus III Ltd | | | George Town, Cayman Islands | |
Thermo Fisher Scientific Cyprus IV C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Cyprus V C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Denmark Senior Holdings ApS | | | Roskilde, Denmark | |
Thermo Fisher Scientific eCommerce Solutions, LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific EMEA Limited | | | Dublin, Ireland | |
Thermo Fisher Scientific Erie 1 Financing (Barbados) SRL | | | Bridgetown, Barbados | |
Thermo Fisher Scientific Erie Financing (Barbados) SRL | | | St. Michael, Barbados | |
Thermo Fisher Scientific Erie Financing S.a r.l | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Falcon Senior Holdings Inc. | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Finance Company B.V. | | | Roosendaal, Netherlands | |
Thermo Fisher Scientific FLC B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific FLC Hong Kong Limited | | | Wanchai, Hong Kong | |
Thermo Fisher Scientific FLC II B.V. | | | Breda, Netherlands. | |
Thermo Fisher Scientific FSIR Financing (Barbados) SRL | | | St. Michael, Barbados | |
Thermo Fisher Scientific FSIR Financing S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific FSUKHCO Financing (Barbados) SRL | | | St. Michael, Barbados | |
Thermo Fisher Scientific GENEART GmbH | | | Regensberg, Germany | |
Thermo Fisher Scientific Germany BV & Co. KG | | | Braunschweig, Germany | |
Thermo Fisher Scientific GmbH | | | Dreieich, Germany | |
Thermo Fisher Scientific Holdings (Cayman) I | | | George Town, Cayman Islands | |
Thermo Fisher Scientific Holdings (Cayman) II | | | George Town, Cayman Islands | |
Thermo Fisher Scientific Holdings Europe Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific HR Services Mexico, S. de R.L. de C.V.
|
| | Monterrey, Nuevo Leon, Mexico | |
Thermo Fisher Scientific India Holding LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific India Pvt Ltd | | | Mumbai, India | |
Thermo Fisher Scientific Investments (Luxembourg) II S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Investments (Luxembourg) S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Investments (Malta) Limited | | | Birkirkara, Malta | |
Thermo Fisher Scientific Investments (Sweden) II LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Investments (Sweden) LLC | | | Dover, Delaware, USA | |
Name of Company
|
| |
Seat
|
|
Thermo Fisher Scientific Investments (Sweden) S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Investments Malta (Sweden Financing) Limited | | | Birkirkara Malta | |
Thermo Fisher Scientific Invitrogen Financing (Barbados) SRL | | | St. Michael, Barbados | |
Thermo Fisher Scientific IT Services GmbH | | | Karlsruhe, Germany | |
Thermo Fisher Scientific Japan Holdings I B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Japan Holdings II B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Japan Holdings III B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific K.K. | | | Tokyo, Japan | |
Thermo Fisher Scientific Korea Ltd. | | | Seoul, Korea | |
Thermo Fisher Scientific Life Canada Holding ULC | | | Halifax, Nova Scotia, Canada | |
Thermo Fisher Scientific Life CV GP Holdings II LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life CV GP Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Enterprises C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life Enterprises GP LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Financing (Barbados) SRL | | | St. Michael, Barbados | |
Thermo Fisher Scientific Life Financing (Cayman) | | | George Town, Cayman Islands | |
Thermo Fisher Scientific Life Financing C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life Financing Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific Life Holdings I C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life Holdings II C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life Holdings III C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life Holdings Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific Life International GP Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life International Holdings I C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life International Holdings II C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life Investments C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life Investments GP LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Investments I S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Life Investments II S.à r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Life Investments IV S.a.r.l | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Life Investments Malta Holding I LLC
|
| | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Investments Malta II Limited | | | Birkirkara, Malta | |
Thermo Fisher Scientific Life Investments US Financing I LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Investments US Financing II LLC
|
| | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Netherlands Holding C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life NL Holdings GP LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Senior GP Holdings II LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Senior GP Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Senior Holdings C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life Senior Holdings II C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Life Senior Holdings, Inc. | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Switzerland Holdings GP LLC | | | Dover, Delaware, USA | |
Name of Company
|
| |
Seat
|
|
Thermo Fisher Scientific Life Tech Korea Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Technologies Enterprise Holding Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific Life Technologies Investment I LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Technologies Investment II LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Life Technologies Investment UK I Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific Life Technologies Investment UK II Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific Life Technologies Investments Holding LP | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific Life Technologies Israel Investment I Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific Life Technologies Israel Investment II Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific Life Technologies Luxembourg Holding LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific LSI Financing (Barbados) SRL | | | St. Michael, Barbados | |
Thermo Fisher Scientific Luxembourg Enterprise Holdings S.à r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Luxembourg German Holdings S.a.r.l.
|
| | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Luxembourg Life Technologies UK Holding S.à r.l | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Luxembourg Sweden Holdings I S.à r.l
|
| | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Luxembourg Sweden Holdings II S.à r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Luxembourg Venture Holdings I S.a.r.l.
|
| | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Luxembourg Venture Holdings II S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Malaysia Sdn. Bhd. | | | Kuala Lumpur, Malaysia | |
Thermo Fisher Scientific Malta Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Messtechnik GmbH | | | Erlangen, Germany | |
Thermo Fisher Scientific Middle East Holdings Inc. | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Milano Srl | | | Rodano, Italy | |
Thermo Fisher Scientific New Zealand Holdings | | | Auckland, New Zealand | |
Thermo Fisher Scientific New Zealand Limited | | | Auckland, New Zealand | |
Thermo Fisher Scientific NHK Limited | | | Causeway Bay, Hong Kong | |
Thermo Fisher Scientific Norway Holdings AS | | | Oslo, Norway | |
Thermo Fisher Scientific Norway US Investments LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Odyssey Financing (Barbados) SRL | | | St. Michael, Barbados | |
Thermo Fisher Scientific Odyssey Holdings Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific One Limited | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific Operating Company LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Oy | | | Vantaa, Finland | |
Thermo Fisher Scientific Panama I Cayman Ltd | | | George Town, Cayman Islands | |
Name of Company
|
| |
Seat
|
|
Thermo Fisher Scientific Peru S.R.L. | | | Lima, Peru | |
Thermo Fisher Scientific PN2 C.V | | | Breda, Netherlands | |
Thermo Fisher Scientific PN2 LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific PNM Limited Liability Partnership | | | Cheshire, United Kingdom | |
Thermo Fisher Scientific PNM S.a.r.l | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific PRB LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific PRB Malta Limited | | | Mriehel, Malta | |
Thermo Fisher Scientific PRB S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Pte. Ltd. | | | Singapore, Singapore | |
Thermo Fisher Scientific Re Ltd. | | | Hamilton, Bermuda | |
Thermo Fisher Scientific Senior Financing LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Senior Holdings Australia LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Senior Holdings LP | | | Saint John, New Brunswick, Canada | |
Thermo Fisher Scientific SL | | | Madrid, Spain | |
Thermo Fisher Scientific Solutions LLC | | | Seoul, Korea | |
Thermo Fisher Scientific South Africa Proprietary Ltd | | | Johannesburg, South Africa | |
Thermo Fisher Scientific SpA | | | Rodano, Italy | |
Thermo Fisher Scientific Spectra LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Spectra Malta Limited | | | Mriehel, Malta | |
Thermo Fisher Scientific Spectra S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg I S.à r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg II S.à r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Spectra-Physics Investments Malta Limited | | | Birkirkara, Malta | |
Thermo Fisher Scientific Sweden Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Sweden Holdings S.a.r.l | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Switzerland B.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Switzerland Holdings C.V. | | | Breda, Netherlands | |
Thermo Fisher Scientific Taiwan Co., Ltd. | | | Taipei City, Taiwan | |
Thermo Fisher Scientific TR Limited | | | Causeway Bay, Hong Kong | |
Thermo Fisher Scientific Vector Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Vector Holdings UAB | | | Vilnius City, Lithuania | |
Thermo Fisher Scientific Vector Senior Holdings I UAB | | | Vilnius City, Lithuania | |
Thermo Fisher Scientific Vector Senior Holdings II UAB | | | Vilnius City, Lithuania | |
Thermo Fisher Scientific West Palm Holdings LLC | | | Dover, Delaware, USA | |
Thermo Fisher Scientific Wissenschaftliche Geräte GmbH | | | Vienna, Austria | |
Thermo Fisher Scientific Worldwide Investments (Cayman) | | | George Town, Cayman Islands | |
Thermo Fisher Scientific Worldwide Investments (Luxembourg) S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Fisher Scientific Worldwide Investments LLC | | | Dover, Delaware, USA | |
Thermo Fisher Senior Canada Holdings LLC | | | Dover, Delaware, USA | |
Name of Company
|
| |
Seat
|
|
Thermo Foundation, Inc. | | | Boston, Massachusetts, USA | |
Thermo Gamma-Metrics Holdings Pty Ltd. | | | Melbourne, Australia | |
Thermo Gamma-Metrics LLC | | | Dover, Delaware, USA | |
Thermo Gamma-Metrics Pty Ltd | | | Melbourne, Australia | |
Thermo Holding European Operations LLC | | | Dover, Delaware, USA | |
Thermo Hypersil Ltd | | | Cheshire, United Kingdom | |
Thermo Hypersil-Keystone LLC | | | Dover, Delaware, USA | |
Thermo Instrument Controls de Mexico, S.A. de C.V. | | | Ciudad de Mexico, Mexico | |
Thermo Kevex X-Ray LLC | | | Dover, Delaware, USA | |
Thermo Keytek LLC | | | Dover, Delaware, USA | |
Thermo LabSystems Inc. | | | Boston, Massachusetts, USA | |
Thermo LabSystems S.A. | | | Madrid, Spain | |
Thermo Life Science International Trading (Tianjin) Co., Ltd. | | | Tianjin, China | |
Thermo Life Sciences AB | | | Uppsala, Sweden | |
Thermo Luxembourg Holding LLC | | | Dover, Delaware, USA | |
Thermo Luxembourg Holding S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Luxembourg S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Luxembourg U.S. S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Measurement Ltd | | | Cheshire, United Kingdom | |
Thermo Measuretech Canada Inc. | | | Toronto, Ontario Canada | |
Thermo MF Physics LLC | | | Dover, Delaware, USA | |
Thermo MT II Limited | | | Birkirkara, Malta | |
Thermo MT II LLC | | | Dover, Delaware, USA | |
Thermo Neslab LLC | | | Concord, New Hampshire | |
Thermo Nicolet Limited | | | Cheshire, United Kingdom | |
Thermo Onix Limited | | | Cheshire, United Kingdom | |
Thermo Optek Limited | | | Cheshire, United Kingdom | |
Thermo Optek S.A. | | | Madrid, Spain | |
Thermo Orion Inc. | | | Boston, Massachusetts, USA | |
Thermo Portable Holdings LLC | | | Dover, Delaware, USA | |
Thermo Power Corporation | | | Boston, Massachusetts, USA | |
Thermo Process Instruments GP, LLC | | | Dover, Delaware, USA | |
Thermo Process Instruments, L.P | | | Austin, Texas, USA | |
Thermo Projects Limited | | | Cheshire, United Kingdom | |
Thermo Quest S.A. | | | Madrid, Spain | |
Thermo Radiometrie Limited | | | Cheshire, United Kingdom | |
Thermo Ramsey Italia S.r.l. | | | Rodano, Italy | |
Thermo Ramsey LLC | | | Boston, Massachusetts, USA | |
Thermo Ramsey S.A. | | | Madrid, Spain | |
Thermo Re, Ltd. | | | Hamilton, Bermuda | |
Thermo Scientific Microbiology Pte Ltd. | | | Singapore, Singapore | |
Thermo Scientific Microbiology Sdn Bhd | | | Kuala Lumpur, Malaysia | |
Thermo Scientific Portable Analytical Instruments Inc. | | | Dover, Delaware, USA | |
Name of Company
|
| |
Seat
|
|
Thermo Scientific Services, Inc. | | | Sacramento, California, USA | |
Thermo Securities Corporation | | | Dover, Delaware, USA | |
Thermo Sentron Canada Inc. | | | Toronto, Ontario, Canada | |
Thermo Sentron Limited | | | Cheshire, United Kingdom | |
Thermo Services (Hungary) Kft | | | Budapest, Hungary | |
Thermo Suomi Holding B.V. | | | Breda, Netherlands | |
Thermo TLH (MT) Limited | | | Mriehel, Malta | |
Thermo TLH (UK) Limited | | | Cheshire, United Kingdom | |
Thermo TLH L.P. | | | Dover, Delaware, USA | |
Thermo TLH Luxembourg S.a.r.l. | | | Luxembourg, Luxembourg | |
Thermo Trace Pty Ltd. | | | Melbourne, Australia | |
Thermo USC I LLC | | | Dover, Delaware, USA | |
Thermo-Fisher Biochemical Product (Beijing) Co., Ltd. | | | Beijing, China | |
ThermoLase LLC | | | Dover, Delaware, USA | |
ThermoSpectra Limited | | | Cheshire, United Kingdom | |
TK Partnership (aka Silent Partnership) | | | Tokyo, Japan | |
TMOI Inc. | | | Dover, Delaware, USA | |
TPI Real Estate Holdings LLC | | | Dover, Delaware, USA | |
Trek Diagnostic Systems LLC | | | Dover, Delaware, USA | |
Trek Diagnostic Systems Ltd. | | | Cheshire, United Kingdom | |
Trek Holding Company II Ltd. | | | Cheshire, United Kingdom | |
Trek Holding Company Ltd. | | | Cheshire, United Kingdom | |
Trex Medical Corporation | | | Dover, Delaware, USA | |
TSP Holdings I LLC | | | Dover, Delaware, USA | |
TWX, LLC | | | Boston, Massachusetts, USA | |
United Diagnostics, Inc. | | | Dover, Delaware, USA | |
USB Corporation | | | Cleveland, Ohio, USA | |
VG Systems Limited | | | Cheshire, United Kingdom | |
Westover Scientific, Inc. | | | Bothell, Washington, USA | |
Name of the Company
|
| |
Seat
|
|
Amnisure International LLC | | | USA; Boston, Massachusetts | |
ATQ Biyoteknoloji iç ve Diş Ticaret Ltd. | | | Turkey; Çankaya — Ankara | |
Cellestis International Pty. Ltd. | | | Australia; Chadstone, Victora | |
Cellestis Pty. Ltd. | | | Australia; Chadstone, Victoria | |
DxS EBT Ltd. | | | United Kingdom; Manchester | |
DxS Ltd. | | | United Kingdom; Manchester | |
Gensutek/Gurmed HPV JV | | | Turkey; Ankara | |
Ingenuity Systems S.R.L. | | | Romania; Cluj Napoca | |
Life Biotech Partners B.V. | | | The Netherlands; Venlo | |
PreAnalytiX GmbH / JV | | | Switzerland; Hombrechtikon | |
Q Biotechnology CV | | | The Netherlands; Venlo | |
QIAGEN Aarhus A/S | | | Denmark; Aarhus | |
QIAGEN AB | | | Sweden; Solna | |
QIAGEN AG | | | Switzerland; Hombrechtikon | |
QIAGEN Australia Holding Pty. Ltd. | | | Australia; Chadstone, Victoria | |
QIAGEN Benelux B.V. | | | The Netherlands; Venlo | |
QIAGEN Beverly LLC | | | USA; Beverly, Massachusetts | |
QIAGEN Biotechnology Malaysia Sdn. Bhd. | | | Malaysia; Kuala Lumpur | |
QIAGEN Biotecnologia Brasil Ltda. | | | Brasil; São Paulo | |
QIAGEN Business Services (Manila), Inc. | | | Philippines; Manila | |
QIAGEN Business Services S.p.z.o.o. | | | Poland; Wroclaw | |
QIAGEN Canada Inc. | | | Canada; Montreal, Quebec | |
QIAGEN China (Shanghai) Co. Ltd. | | | China; Shanghai | |
QIAGEN Deutschland Finance Holding (Luxembourg) SARL | | | Luxembourg, Luxembourg | |
QIAGEN Deutschland Holding GmbH | | | Germany; Hilden | |
QIAGEN Distribution B.V. | | | The Netherlands; Venlo | |
QIAGEN Egypt Ltd. | | | Egypt; New Cairo | |
QIAGEN Finance (Malta) Ltd. | | | Malta; Mt-Gzira | |
QIAGEN France S.A.S. | | | France; Courtaboeuf | |
QIAGEN Gaithersburg LLC | | |
USA; Germantown, Maryland
|
|
QIAGEN GmbH | | | Germany; Hilden | |
QIAGEN Hamburg GmbH | | | Germany; Hilden | |
QIAGEN Healthcare Biotechnologies LLC | | |
USA; Wilmington, County of
New Castle, Delaware |
|
QIAGEN Healthcare Biotechnologies Ltd. | | | United Kingdom; Manchester | |
QIAGEN Healthcare Biotechnologies Systems Ltd. | | | United Kingdom; Manchester | |
QIAGEN Hongkong Pte. Ltd. | | | China; Hong Kong | |
QIAGEN Iberia, S.L. | | | Spain; Las Matas (Madrid) | |
QIAGEN Inc. | | | Canada; Toronto, Ontario | |
QIAGEN India Pvt. Ltd. | | | India; New Delhi | |
Name of the Company
|
| |
Seat
|
|
QIAGEN Instruments AG | | | Switzerland; Hombrechtikon | |
QIAGEN K.K. | | | Japan; Tokyo | |
QIAGEN Korea Ltd. | | | Korea; Seoul | |
QIAGEN Lake Constance GmbH | | | Germany; Stockach | |
QIAGEN LLC | | |
USA; Germantown, Maryland
|
|
QIAGEN Ltd. | | | United Kingdom; Manchester | |
QIAGEN Manchester Ltd. | | | United Kingdom; Manchester | |
QIAGEN Mansfield, Inc. | | |
USA; Mansfield, Massachusetts
|
|
QIAGEN Marseille S.A.S. | | | France; Les Ulis | |
QIAGEN México S. De R.L. de C.V. | | | Mexico; Mexico City | |
QIAGEN Middle East and Africa | | | United Arab Emirates; Dubai | |
QIAGEN Monheim GmbH & Co. KG | | | Germany; Hilden | |
QIAGEN North American Holdings Inc. | | | USA; Valencia, California | |
QIAGEN Polska Sp.z.o.o. | | | Poland; Wroclaw | |
QIAGEN Pty. Ltd. | | | Australia; Melbourne, Victoria | |
QIAGEN Redwood City Inc. | | |
USA; Redwood City, California
|
|
QIAGEN Rus LLC | | | Russia; Moskau | |
QIAGEN S.r.l. | | | Italy; Mailand | |
QIAGEN Sciences LLC | | |
USA; Germantown, Maryland
|
|
QIAGEN Servicios México S. de R.L. de C.V. | | | Mexico; Mexico City | |
QIAGEN Shared Services LLC | | |
USA; Germantown, Maryland
|
|
QIAGEN Shenzhen Co. Ltd. | | | China; Shenzhen | |
QIAGEN Singapore Pte. Ltd. | | | Singapore | |
QIAGEN South Africa Pty. Ltd. | | | South Africa; Johannesburg | |
QIAGEN Taiwan Co. Ltd. | | | Taiwan; Taipei | |
QIAGEN Thailand | | | Thailand; Bangkok | |
QIAGEN Treasury Management Services Ltd. | | | United Arab Emirates; Dubai | |
QIAGEN U.S. Finance Holdings (Luxembourg) SARL | | | Luxembourg, Luxembourg | |
QIAGEN U.S. Finance LLC | | |
USA; Germantown, Maryland
|
|
QIAGEN U.S. Finance Ltd. | | | Ireland; Dublin | |
QIAGEN US REAL ESTATE MANAGEMENT LLC | | |
USA; Germantown, Maryland
|
|
Research Biolabs Pte. Ltd. | | | Singapore | |
Scandinavian Gene Synthesis (SGS) AB | | | Sweden; Köping | |
STAT-Dx Life S.L. | | | Spain; Barcelona | |
TianGen Biotech (Beijing) Co. Ltd. | | | China; Peking | |
|
Quebec B.V.
Takkebijsters 1 4817 BL Breda The Netherlands |
| | | |
| (This translation is non-binding and will not be signed) | | | (This translation is non-binding and will not be signed) | |
| | | | ||
|
Dorothee Blessing
Managing Director |
| |
Florian Roeckl
Managing Director |
|
|
/s/ Jan Weber
Jan Weber
Managing Director Morgan Stanley & Co International plc |
| |
|
|